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Abstract 
 
Pendrin is an anion exchanger transporting several monovalent anions including 
iodide, chloride and bicarbonate. It is expressed in the inner ear, thyroid and kidney and 
more recently was also detected in the airways and in a number of other tissues. Pendrin 
was first identified as the protein whose mutations leading to a reduction or loss of 
transport function are responsible for the pathology referred to as Pendred syndrome, an 
autosomal recessive disorder characterized by bilateral sensorineural hearing loss 
associated to thyroid dysfunction with or without involvement of the vestibular system. 
Pendrin mutations also lead to the development of unilateral or bilateral hearing loss with 
enlargement of the vestibular aqueduct with no involvement of other organs (non-
syndromic EVA). On the other hand, the overexpression and hyper-function of pendrin 
have been recently associated with a number of other pathologies, such as hypertension, 
bronchial asthma and chronic obstructive pulmonary disease (COPD).   
 
The high phenotypic variability among individuals carrying pendrin mutations, the 
existence of phenocopies of Pendred syndrome and the high incidence of benign 
polymorphisms in the general population require both the sequencing of the pendrin 
coding region and assessment of the possible functional impairment of the identified 
protein variants in order to confirm or exclude the role of pendrin in determining deafness. 
In this work, we performed the functional characterization of 7 pendrin variants identified in 
a cohort of 58 deaf patients by our collaborators of the University of Campinas (Sao Paolo, 
Brazil). The analysis of pendrin activity was performed measuring the iodide influx in 
pendrin transfected cells by means of a fluorometric assay based on an enhanced yellow 
fluorescence protein (EYFP) variant sensitive to the intracellular iodide concentration. 
Furthermore, the molecular defect of such mutants was analyzed, defining their subcellular 
localization and expression levels by means of confocal microscopy and western blot.  
 
Based on the results of the functional test, 4 pendrin variants (P142L, G149R, 
C282Y and Q413R) were classified as mutations with reduction of function, 2 (T193I and 
L445W) as mutations with loss of function and one (R776C) as a benign polymorphism. 
Assessing the degree of functional impairment of the analyzed pendrin variants 
contributed to the genetic diagnosis of the screened patients. Including our findings, the 
genetic diagnosis was conclusive for 6 patients (for 5 of them deafness was assessed as 
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linked to pendrin dysfunction and for one patient we were able to exclude pendrin as the 
genetic cause of deafness) while for 8 individuals, bearing monoallelic pendrin mutations, 
further investigations are needed, involving pendrin promoter and 3’-UTR, as well as 
further deafness related genes. 
 
We could observe a clear correlation between measured functional impairment, 
sub-cellular localization and expression levels of these specific variants. In particular, 
mutants with loss of function (pendrin T193I and L445W) are retained in the ER, 
completely excluded from the plasma membrane and their expression levels are greatly 
reduced with respect to the wild type, while mutants with reduction of function (pendrin 
P142L, G149R, C282Y) show at least a partial trafficking to the PM and expression levels 
reduced with respect to the wild type but significantly higher with respect to the mutants 
with loss of function.  
 
Based on the finding that expression levels of all pendrin mutants are reduced 
compared to the wild type, we hypothesized that they may be targeted for proteasomal 
degradation. Starting from this hypothesis we could show that pharmacological inhibition 
of proteasomal degradation with 10 µM MG132 was capable to recover (i) total and (ii) 
plasma membrane expression levels of pendrin variants and, most importantly, (iii) 
transport activity of specific mutants (pendrin P142L, T183I, Q413R, L445W) was 
improved upon treatment. These results allow for further development of possible 
approaches aimed to rescue pendrin transport activity as a potential treatment of 
pathologies related to pendrin malfunction. 
 
The second part of the present study focuses on the search of a specific inhibitor of 
pendrin. No specific, non-toxic and potent inhibitors of pendrin could be identified so far 
and the screening of large compound libraries failed in identifying potential ligands. We 
therefore adopted a more targeted selection of candidate ligands to be submitted to the 
functional screening. We selected compounds among (i) established inhibitors of anion 
exchangers, (ii) inhibitors of the pendrin homologue DRA, (iii) commonly used diuretics 
and antihypertensive agents, and (iv) small molecules predicted via two bioinformatic 
tools, the meta-analysis and SHED alignments. Meta-analysis is an approach aimed to the 
mathematical definition of a protein topology based on its primary aminoacidic sequence, 
with no knowledge of its three-dimensional structure. SHED profile allows for the 
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mathematical definition of small compounds according to the intra-molecular distribution of 
specific atomic features. The effect of the candidate ligands on pendrin activity was 
evaluated by means of the same fluorometric assay mentioned earlier. In the present 
study we could (i) confirm the inhibitory effect of the previously assessed active 
compounds niflumic acid and 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB) and 
(ii) show for the first time the inhibitory effect of the anti-inflammatory, anti-rheumatic drug 
tenidap. In a second phase screening of further compounds suggested by the alignment of 
niflumic acid and tenidap, according to the SHED profiling, we were able to identify two 
additional active compounds, N-(2-chlorophenyl)-2-(2,4-dibromophenoxy)acetamide and 
flufenamic acid. The identification of pendrin inhibitors may represent an important step in 
the treatment of pathological conditions associated to an increased pendrin function or 
expression. 
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1.1 The anion transporter pendrin 
 
Pendrin is an electroneutral anion exchanger [1] with affinity for a number of ions 
including iodide, chloride, formate, thyocianate, hydroxide and bicarbonate. It was initially 
described to be expressed in the inner ear [2], thyroid [3] and kidney [4], but more recently 
it has also been detected in the airways [5] and in a number of other tissues [6, 7], even 
though its role in most cases is still to be elucidated.  
 
Pendrin was first cloned by Everett et al. in 1997 [8] and identified as the protein that, 
if mutated and non-functional or hypo-functional, is responsible for the pathology referred 
to as Pendred syndrome [8], an autosomal recessive disorder described for the first time in 
1896 by the English physician Vaughan Pendred [9]. Pendred syndrome is characterized 
by bilateral sensorineural hearing loss associated with thyroid dysfunction and possibly 
goiter [10]. Pendrin-related deafness can be either syndromic or non-syndromic and it is 
usually characterized by an enlargement of the vestibular aqueduct (EVA). More recently, 
the deregulation of the transporter has been associated with other pathological issues and 
in particular its over-expression and/or hyper-function have been linked to hypertension 
[11] and airway distresses such as bronchial asthma and chronic obstructive pulmonary 
disease (COPD) [12].  
 
In the inner ear (Figure 1a), pendrin is mainly expressed in the external sulcus and 
spiral prominence cells of the cochlea, in the mitochondria-rich cells of the endolymphatic 
sac and duct and in the transitional cells surrounding the sensory epithelia in the utricle, 
saccule and ampullae of the vestibular labyrinth [13]. In all the above mentioned 
compartments, pendrin is responsible for the exchange of chloride and bicarbonate [14], 
contributing to the regulation of the pH and ion composition of the endolymph, therefore 
maintaining the endocochlear potential, essential for the conversion of the acoustic signal 
in electric impulse. In case of an impaired pendrin activity, acidification of pH and alteration 
of the ion homeostasis of the endolymph are associated with EVA (Figure 1b) [15], 
degeneration of sensory cells, loss of endocochlear potential [16] and formation of calcium 
oxalate stones in the utricle and saccule [17]. Altogether these defects result in the 
development of severe to profound deafness, either syndromic or non-syndromic (i.e. 
accompanied or not with thyroid dysfunction, respectively), possibly associated in the 
worst cases with vestibular dysfunction. The role of pendrin appears to be crucial in the 
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correct maturation of the inner ear. Thanks to an inducible pendrin knock-out mouse, it has 
been shown that a loss of the transporter function between embryonic day 16.5 and 
postnatal day 2 leads to all the defects reported above and to an irreversible failure in 
developing a normal hearing phenotype [18]. 
 
 
 
 
In the thyroid (Figure 2), pendrin is abundantly expressed on the apical membrane of 
the thyrocytes [19], where, together with the Na+ iodide symporter (NIS) at the basolateral 
side, contributes to the trans-epithelial transport of iodide from the bloodstream to the 
follicular lumen of the gland [20]. Iodide is then organified on thyroglobulin as an essential 
step in thyroid hormones biosynthesis. Although the function of pendrin in the thyroid is 
controversial [21], it is widely accepted that it may act as a Cl-/I- exchanger. A lack of 
pendrin activity would lead to a reduced iodide flux into the follicular lumen and, as a 
consequence, to the partial iodide organification defect seen in Pendred syndrome, 
eventually leading to hypothyroidism and/or goiter [22, 23]. The severity of the thyroidal 
phenotype appears to be extremely variable also within families [22] and can often be 
identified only by a positive perchlorate discharge test [24]. It is commonly hypothesized 
that further genetic or environmental factors may contribute to the incidence and the 
Endolympha+c-sac-
Ampullae-
Utricle-
Saccule-
Cochlea-
 
Figure 1: a) Schematic depiction of pendrin expression pattern in the inner ear; b) pendrin 
knock-out leads to loss of ion homeostasis of the endolymph, resulting in the enlargement of 
the whole vestibular aqueduct (EVA). ES: endolymphatic sac, ED: endolymphatic duct, S: 
saccule, CO: cochlea (Choi, B.Y., et al. The Journal of clinical investigation, 2011. 121: 4516-
25). 
a)	   b)	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severity of the thyroid phenotype. A specific example is represented by the dietary iodide 
intake, that has been shown to strongly influence the incidence of the development of 
pendrin-related hypothyroidism and goiter in different populations [25]. 
 
 
 
In the kidney (Figure 3), pendrin has been identified on the apical membrane of β and 
non-α, non-β intercalated cells of the distal convoluted tubule, cortical collecting duct and 
connecting tubule [4, 26, 27]. Similarly to the inner ear, in the kidney pendrin is responsible 
for the exchange of Cl-/OH- or Cl-/HCO3- [4], therefore conditioning the pH of the urine and 
contributing to the pH homeostasis of the whole organism. In addition to the HCO3- 
secretion, together with the epithelial Na+ channel (ENaC) pendrin participates in the 
reabsorption of NaCl from the urine to the bloodstream [28], therefore contributing to the 
blood pressure regulation [29].  
Figure 2: schematic representation of transepithelial iodide transport in the thyroid follicle. 
Pendrin is expressed at the apical side of thyrocytes and, together with the Na+/I- symporter 
NIS at the baso-lateral side, allows for the transport of iodide from the bloodstream into the 
lumen of the follicle, where it is organified in the thyroid hormones T3 (Triiodothyronine) and 
T4 (Thyroxine) (modified from: Boron, W.F. Medical physiology: A Cellular and Molecular 
Approach. 2003: W.B. Saunders). 
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However, Pendred syndrome patients show no renal dysfunction, suggesting the 
presence of redundant mechanisms compensating for the lack of functional pendrin in the 
kidney under basal conditions. Interestingly, cases of metabolic alkalosis have been 
recently detected in Pendred patients, in association with pharmacological treatment with 
thiazides [30] or disturbed acid-base homeostasis due to inter-current illness [31]. The 
involvement of pendrin in pH homeostasis and salt reabsorption has also been confirmed 
in mouse models lacking pendrin expression. Recently, different groups showed an 
alteration of bicarbonate secretion in the kidney in pendrin knock-out mice, leading to 
metabolic alkalosis both in the basal state [32] and upon NaCl restriction [33]. 
Furthermore, Verlander et al. demonstrated that pendrin knock-out mice are resistant to 
aldosterone-analogs-induced hypertension, but develop metabolic alkalosis following 
aldosterone treatment [11]. 
 
 
 
 
Figure 3: schematic representation of pendrin expression in the distal section of the nephron. Pendrin is 
expressed in β and non-α non-β intercalated cells of distal convoluted tubule, cortical collecting duct and 
connecting tubule. It exerts a Cl-/HCO3- transport contributing on one side to the regulation of pH and on 
the other side, together with ENaC in the principal cells, to the transepithelial reabsorption of NaCl. DCT: 
distal convoluted tubule, CD: Collecting duct (modified from: OpenStax College, Anatomy & Physiology. 
OpenStax College. 25 April 2013. <http://cnx.org/content/col11496/latest/>). 
Glomerular)capsule)
Proximal)tubule)
DCT)
CT)
Loop$of$Henle!
  
  
  
Pendrin!
  
  Cl#!
HCO3#!   ATP!
3*Na+!
2*K+!
 Cl#!
  
  ATP! 3*Na+!2*K+!
 
    H2O! H2O!
  
  Na+!ENaC!
AQP2! AQP3,4!
  
  
  
Lumen! Blood!
    
  
  
β*intercalated*cell!
Principal*cell!
  CA!
H2O*+*CO2*!
HCO3#!+!H+!
  ATP! Na+!H+!
D 
	  	   	  16	  
As already mentioned, the expression of pendrin has been recently identified in tissues 
other than the inner ear, thyroid and kidney, such as airways [34], mammary gland [35], 
placenta [36], testis [37], endometrium [38] and liver [39]. In most of the cases, the 
pathophysiological role of pendrin is still to be elucidated. A notable exception is the 
expression of pendrin in the airways, where the transporter has been shown to play a 
crucial role in the exacerbation of symptoms typical of airway distresses such as asthma 
and COPD. Overexpression and hyperactivity of pendrin in the upper airways have been 
shown to be associated with inflammatory states characterized by stimulation via 
inflammatory cytokines, in particular interlukin-4, -13 and -17 [12, 34, 40].  
The role of pendrin overexpression and hyperactivity in the airways will be discussed 
more in detail in later sections. 
  
1.2 Putative structure of pendrin 
 
Structural and topological definition of pendrin is still an elusive issue, as it is often 
the case of membrane proteins. Due to their high degree of flexibility and hydrophobicity, 
the experimental definition of three-dimensional structures for those proteins is still a real 
challenge, either by X-ray crystallography or nuclear magnetic resonance (NMR) [41]. 
Since its cloning in 1997 [8], a number of models have been suggested in an attempt of 
defining pendrin structure, according to different predictor approaches. At first, an 11 
transmembrane segments model with the N-terminus located on the intracellular side and 
the C-terminus located on the extracellular side was predicted with the PHDhtm algorithm 
[8]. Royaux et al. adapted this early model with an additional transmembrane segment, 
therefore bringing the C-terminus on the intracellular side [3]. The intracellular localization 
of both N-terminus and C-terminus was experimentally supported by Gillam et al. in 2004, 
demonstrating that immunostaining of a hexahistidine tag fused either to the C-terminus or 
N-terminus of pendrin is only possible after membrane permeabilization [42]. Further 
supporting the intracellular localization of the C-terminus of pendrin, is the presence of a 
sulfate transporter antisigma factor antagonist (STAS) domain. The exact function of such 
domain is still to be elucidated, but it is supposed to be involved in the regulation of the 
transport activity via binding and hydrolysis of intracellular nucleotides [43]. In a 
comprehensive review, Dossena et al. [44] suggested a further model, predicted by the 
MEMSAT algorithm and adjusted according to the simple transmembrane alignment 
method (STAM) proposed by Shafrir and Guy [45]. Such model is characterized by 15 
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transmembrane segments with the N-terminus on the extracellular side and the C-terminus 
on the intracellular side (Figure 4). The 15 transmembrane segments include 2 amphipatic 
regions, whose localization may either be intracellular, extracellular or transmembrane, 
shifting therefore the number of transmembrane segments from 15 to 14 or 13. 
 
 
It is anyhow important to point out that all of the abovementioned models are only 
speculative and lack of experimental validation. In the present study, I will refer to the last 
model described, suggested by Dossena et al. in 2009. In Figure 4, this model is 
graphically represented and some notable features are marked. At the C-terminus of 
pendrin (intracellular side), the sequence corresponding to the STAS domain is 
represented in light blue. In the 3rd transmembrane segment, the sulfate transport 
consensus sequence is marked. This sequence is present in all members of the SLC26 
family of transporters, but, in the case of pendrin, it is slightly modified, consistently with 
the observation that pendrin, other than the other members of the family, is not reported to 
transport sulfate. The squared sequences correspond to the amphipatic segments, whose 
localization is ambiguous. The glycines marked in yellow have been recognized as 
Figure 4: putative model of pendrin, as suggested by Dossena et al. in 2009, based on the 
algorithm MEMSAT and STAM. Highlighted features in the figure are the amphipatic segments 
(squared), the sulfate transport consensus sequence (purple) the glycophorin-A like motifs (yellow 
Gs), the STAS domain (light blue), the glycosylation sites (orange) and the polyubiquitilation sites 
(grey) (Modified from: Dossena, S. et al. Journal of molecular endocrinology, 2009. 43:93-103). 
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Glycophorin-A like motifs (GxxxG, where G is glicine and x any bulkier amino acid), whose 
presence is supposed to determine protein dimerization interfaces. In particular, the 
repetition in tandem of three of such motifs in the 15th transmembrane segment appears 
to be crucial for pendrin dimerization (Dossena and Paulmichl, manuscript in preparation). 
Other notable features represented on the model are 4 polyubiquitination sites at the C-
terminus of the protein (highlighted in grey in Figure 4) (http://www.ubpred.org/), in 
accordance with the experimental observation that pendrin is targeted by poly-
ubiquitination enzymes [46]. Furthermore, it was shown that pendrin is glycosylated and 
that such modification influences its dependence from intracellular pH. The two 
experimentally identified glycosylation sites, asparagine 167 and asparagine 172, are 
marked in orange in Figure 4 [47]. 
 
1.3 The correlation of genotype and phenotype 
 
As previously mentioned, the main pathological issue linked to an impaired transport 
activity of pendrin is the development of deafness, either syndromic or non-syndromic, 
typically associated with an enlargement of the vestibular aqueduct detectable by 
computer tomography (CT) scan. Pendrin-related deafness is the most common form of 
syndromic hearing loss worldwide. Furthermore, pendrin is also involved in a large number 
of cases of non-syndromic deafness. It has been estimated that Pendred syndrome-
related deafness may contribute to about 7.5 % of the reported cases of hereditary 
deafness [48] but the actual incidence of pendrin-related deafness has not been 
determined, mainly due to variable symptomatology penetrance [49]. An early diagnosis of 
deafness, at best within the first 6 months of life of the newborn, together with an efficient 
planning of the intervention, are crucial for language development and future integration of 
the individual in school and society, giving him/her the same chances of success of any 
normal hearing person [50, 51]. The intervention must include professional counseling of 
the family on how to deal with the diagnosed deaf baby, as well as early enrollment in 
specific assistance programs aimed to the development of proficient communication skills 
from the early age. Together with an early diagnosis, the definition of the specific genetic 
or environmental cause of the sensory defect is an essential step in the view of a possible 
counseling and intervention plan with the patient and the family, as well as for a possible 
therapeutical intervention, where available. For this reason, it is extremely important to 
develop an efficient and standardized hearing screening program for newborns [52] or, in 
	  	   	  19	  
an ideal situation, a genetic screening, in order to determine as early as possible the 
chances of developing a hearing loss phenotype in correlation with the detected genotype. 
For what concerns pendrin-related deafness, more than 200 pendrin allelic variants have 
been detected so far in the deaf population worldwide 
(www.healthcare.uiowa.edu/labs/pendredandbor/slcMutations.htm). Some of the identified 
variants have been detected both in the deaf and normal hearing population, therefore 
candidating them to the status of benign polymorphisms. The identified mutations can be 
divided in aminoacidic substitutions (missense), insertions or deletions (some of which 
determine a frameshift and premature truncation of the protein), splice-site variants. 
Mutations are widespread throughout the whole pendrin coding region and promoter, and 
no hot-spots can be identified within the protein sequence. Despite the large number of 
pendrin mutations identified, in very few cases the actual role of the specific variant 
detected in the patient is clearly defined, as no functional test is routinely performed, 
preventing any clear correlation between the observed phenotype and the identified 
genotype. Furthermore, in those cases of functionally characterized variants, the degree of 
the experimentally determined functional impairment does not always reflects the severity 
of the observed symptoms. Symptoms related to pendrin dysfunction range from mild 
unilateral hearing loss to the full spectrum of defects typical of the syndrome. Furthermore, 
the same mutation can be found both in the deaf and in the healthy population or 
associated to different degrees of severity of hearing loss in different patients, therefore 
suggesting a more complex picture in the etiology of pendrin-related hearing defects, 
rather than a simple monogenic defect. The classical paradigm elaborated in the attempt 
of correlating genotype and phenotype stated that biallelic mutations leading to complete 
loss of function of the pendrin protein are necessary and sufficient for the development of 
Pendred syndrome, whereas those mutations leading to a reduction of function but not a 
complete abrogation of the transport activity were considered to be responsible for the 
development of non-syndromic deafness with unilateral or bilateral EVA [53]. Lately 
however, with the increasing number of mutations characterized on a functional level, it 
became clear that such a simple and linear correlation is to be excluded, and more 
complex genetic and environmental factors have to be taken into account [53] in order to 
clearly explain the phenotypic diversity of pendrin-related deafness.  
 
For an exact identification of the cause of deafness, it is therefore necessary to 
consider the role played by the specific mutant together with other molecular entities (such 
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as transcription factors) and environmental factors (such as infections and traumas) often 
responsible for the aggravation of the hearing loss phenotype. 
 
  1.3.1 Functional characterization of pendrin mutations  
  found in the Brazilian deaf population 
 
The functional characterization of pendrin allelic variants identified in deaf patients in 
different populations is an essential step to define the role of pendrin in determining the 
hearing loss phenotype. Furthermore, the assessment of a correlation between genotype 
and phenotype would provide important insights in the definition of the global picture of 
pendrin-related deafness, as an index of the relevance of pendrin in determining the 
sensory defect worldwide. In this view, an efficient interplay between (i) clinical diagnosis 
of deafness, (ii) identification of the possible genetic determinants and (iii) validation of the 
role of the candidate molecular targets by means of functional and molecular tests is 
clearly necessary.  
 
Thanks to the collaboration with the Center of Molecular Biology and Genetic 
Engineering at the State University of Campinas, Sao Paolo, Brazil (Prof. Edi Lucia 
Sartorato), we could access a cohort of Brazilian patients referring for deafness (with or 
without EVA) at the general hospital of Campinas. Our collaborators recently started a 
genetic screening with the aim of assessing the prevalence of the different genetic causes 
of deafness within the Brazilian population, or at least a portion of it. For some of the 
patients of this cohort, mutations in the pendrin coding sequence were found. We then 
performed the functional and molecular characterization of pendrin allelic variants detected 
in this cohort in order to assess the specific role of pendrin in determining deafness, i.e. to 
discriminate between pathological mutations and benign polymorphisms. In Brazil, about 
18 million people, corresponding approximately to 9% of the population, are recognized 
with a degree of hearing impairment. Both genetic and environmental factors (mainly 
rubella infection, perinatal anoxia and meningitis) account for the development of deafness 
[54], with the environmental causes having a major role on the incidence of the sensory 
defect, especially in those vast areas of the country that lack an efficient health care 
system. The recent improvement of the health system throughout the country is rapidly 
increasing the impact of genetic factors with respect to the environmental ones, calling 
therefore for a greater attention in the investigation of the genetic causes of the disease. 
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However, the genetic factors determining the development of deafness are still poorly 
investigated in Brazil, and the interest in pendrin-related syndromic and non-syndromic 
deafness is almost a complete novelty. Before the present study, very little was known on 
the etiology of deafness in Brazil, especially regarding the role and incidence of pendrin 
mutations in the sensory defect [55]. For what concerns the specific role of pendrin in 
determining deafness in Brazil, only isolated cases of mutations [55, 56] in the pendrin 
coding gene (SLC26A4) have been reported in the literature so far (the truncations 96X, 
430X and 453X, the missense mutations F667C, G497S and I490L and the single 
nucleotide deletion of a thymine at the position 1197 of pendrin mRNA, resulting in a 
premature truncation of the protein) [55-57], and for none of them a functional 
characterization of the corresponding protein variants was performed. This work is 
therefore the first aiming to the functional and molecular characterization of pendrin 
variants detected in Brazilian deaf patients, and may therefore contribute to spread light on 
the genetic determinants of deafness in this population. 
 
Deafness is the most common sensory defect in developed countries, estimated to 
affect one in 500 newborns [58]. It can be either syndromic (e.g. associated with 
pathological defects outside the hearing organ) or, in most cases, non-syndromic. More 
than 50% of the reported cases of deafness worldwide are attributed to the so-called 
DFNB1 disorder, caused by mutations in the connexin-26 and connexin-30 coding genes, 
respectively the gap junction proteins B2 and B6 (GJB2 and GJB6) [59]. Altogether, more 
than 80 different genetic loci and 30 genes are expected to contribute to the development 
of some degree of hearing loss, with different prevalence in different populations. The 
genetic screening carried out by our collaborators focused on the most common deafness-
related genes, taking into account both syndromic and non-syndromic forms of deafness, 
as described in the following. The first target gene considered was the connexin-26 coding 
gene GJB2, known to be responsible for the majority of cases of non-syndromic deafness 
in the Brazilian and ethnically related (Spanish, Italian, Portuguese) populations [60]. As a 
first step, the GJB2 coding region containing the most common deafness-causing 
mutation, i.e. a deletion of a guanine at position 35 of the transcript (35delG) [61], was 
sequenced and analyzed. The presence of this particular deletion causes a frame shift in 
the open reading frame and creates a premature STOP codon, leading to the production 
of a truncated form of the protein. The truncated protein resulting from the deletion is 
unable to homo- and/or hetero-dimerize and cannot form a functional gap-junction 
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between neighboring cells, resulting in an impaired intercellular potassium flux in the 
cochlea, essential for hearing function [62]. In those cases where no 35delG mutation 
could be identified, the whole GJB2 coding sequence was sequenced and analyzed, 
looking for other possible mutations in different regions of the gene. Mutations other than 
35delG are much less frequent but may still account for a number of cases of non-
syndromic hearing loss [63]. If no mutations were found in the whole GJB2 coding 
sequence, the further step consisted in the screening of the second most common 
deafness-causing gene, GJB6, coding for a functionally related gap-junction-forming 
protein, connexin-30. The analysis of the GJB6 gene was specifically focused on the 
identification of two common genomic deletions, i.e. del(GJB6-D13S1830) and del(GJB6-
D13S1854) [64], resulting in a lack of expression of connexin-30. If neither mutations in 
GJB2 nor the two GJB6 genomic deletions were detected, the further step was the 
sequencing of the mitochondrial encoded 12S RNA, MTRNR1, with the aim of verifying the 
presence of the nucleotidic substitution A1555G, a mutation found to be related to 
aminoglycoside-induced and/or non-syndromic deafness [65]. When the molecular cause 
of deafness could not be identified in a defect of the aforementioned genes, other known 
deafness-related genes have been sequenced and analyzed, with a particular attention to 
the pendrin coding gene, SLC26A4, as one of the most common genetic causes of 
syndromic deafness. 
 
The sequencing of the 20 coding exons of SLC26A4 involved a total of 58 deaf 
patients (30 females and 28 males aged between 4 and 55 years) divided in two groups 
according to the recorded diagnosis: a first group of 26 patients diagnosed deaf with an 
enlargement of the vestibular aqueduct (EVA) observed via CT scan, while a second 
group of 32 patients identified as deaf, but without any over-the-threshold enlargement of 
the vestibular aqueduct. Sequencing and analysis of the SLC26A4 coding region of the 
patients in the abovementioned two groups lead to the identification of 14 different allelic 
variants [66], including 11 known (the missense mutations T193I, R409H, T410M, Q413R, 
L445W, V609G, R776C and V138F, the deletion del297T and the splice site mutations 
IVS15+5G>A and IVS8+1G>A) and 3 novel (P142L, G149R and C282Y) mutations (Table 
1). Some of the known allelic variants had already been functionally and/or molecularly 
characterized and have been identified as disease-causing mutations, while 6 of the 
identified mutations had not yet been characterized, neither functionally nor molecularly, 
and were included in the present study. In addition, the aminoacidic substitution R776C 
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was included in the study because controversial results regarding its transport ability are 
present in the literature [67, 68] (further details on the genetic screening are given in the 
next section). In order to determine whether the uncharacterized SLC26A4 allelic variants 
identified in this screening do have a role in the development of deafness in this cohort, a 
functional characterization has been performed in our laboratory by means of the 
fluorometric method developed by Dossena et al. in 2006. This method requires the co-
transfection in human embryonic kidney (HEK) 293 Phoenix cells of the cDNA coding for 
the wild type or mutant form of pendrin and a fluorophore (a modified enhanced yellow 
fluorescent protein, EYFP) sensitive to the intracellular iodide concentration (see Methods 
for further details) [69].  
 
  1.3.2 Outcome of genetic screening of the pendrin coding  
  region in a cohort of Brazilian deaf patients 
 
As previously mentioned, the genetic screening was carried on by our collaborators 
at the State University of Campinas on a group of 58 deaf patients, 26 patients with and 32 
patients without EVA. The sequencing and analysis of the coding region of pendrin in the 
selected individuals led to the identification of 14 patients bearing mutations in the pendrin 
coding sequence (Table 1). 9 of these patients belong to the group of deaf individuals with 
EVA and 5 patients belong to the group with no EVA. The identified pendrin allelic variants 
can be divided in 11 missense mutations leading to an aminoacidic substitution (P142L, 
G149R, T193I, R409H, T410M, Q413R, L445W, V609G, R776C, V138F and C282Y), 2 
splice site mutations (IVS15+5G>A and IVS8+1G>A) and 1 single residue deletion 
(del297T), leading to a premature truncation of the protein after the first transmembrane 
segment (Table 1). Eight of the missense mutations identified (T193I, R409H, T410M, 
Q413R, V138F, L445W, V609G, R776C) have already been reported in the literature and 
in part characterized by us or others [67, 68, 70-73]; P142L and G149R were firstly 
identified in this screening and published in 2013 by de Moraes et al. [66] but in that 
particular study they were not characterized neither on a functional nor on a molecular 
level. One allelic variant, namely C282Y, is instead completely novel, neither 
communicated nor characterized previously. 6 of the identified variants (G149R, T193I, 
V609G, R776C, V138F, C282Y) were detected in heterozygosis with the wild type allele in 
9 patients, while in 4 patients (21AA, 02AA, 06AA, 23AA) pendrin variants were detected 
in compound heterozygosis (i.e. both alleles are mutated and the two mutations are 
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different from each other). Interestingly, the aminoacidic substitution V609G has been 
detected in heterozygosis with the wild type allele both in deaf patients presenting EVA 
and in deaf patients with no EVA. In patient 22AA, the R409H mutation was found in 
homozygosis (i.e. both pendrin alleles show the same mutation). In patients C26 and 
L1AA, monoallelic pendrin mutations were detected in combination with a monoallelic 
mutation (35delG) in GJB2, the connexin-26 coding gene previously sequenced. The 
question marks reported in Table 1 identify the detected allelic variants of pendrin lacking 
a functional and/or molecular characterization in the present literature and therefore 
preventing a complete genetic diagnosis of the sensory defect in that specific patient. 
Importantly, total expression levels were never investigated for pendrin variants. In Figure 
5 the distribution of the aminoacidic substitutions identified in the cohort are reported on 
the putative model of pendrin suggested by Dossena et al. in 2009. 
 
Patient 
(n=58) 
Nucleotide 
substitution 
Aminoacid 
substitution 
Patient Genotype 
(coding region) 
Goiter Function Localiz. 
 
Patients deaf with EVA (n=26) 
 
21AA 425C>T P142L P142L/del 297T No ? ? 
16AA 446G>A G149R G149R/WT No ? ? 
18AA 578C>T T193I T193I/WT No ? ? 
22AA 1226G>A R409H R409H/R409H No lost/red. 
[74] 
partially 
PM 
02AA 1229C>T T410M T410M/IVS15+5G>A      No lost [73] ER [73] 
06AA 1238A>G Q413R Q413R/V138F No ? ? 
23AA 1334T>G L445W L445W/IVS8+1G>A Yes ? ? 
L1AA 1286T>G V609G V609G/WT * No reduced 
[71] 
? 
15AA 2326C>T R776C R776C/WT No ? ? 
 Patients deaf without EVA (n=32)  
C15 412G>T V138F V138F/WT No lost [73] ER [73] 
C26 845G>A C282Y C282Y/WT * No ? ? 
C01 1286T>G V609G V609G/WT No reduced 
[71] 
? 
C04 1286T>G V609G V609G/WT No reduced 
[71] 
? 
C09 1286T>G V609G V609G/WT No reduced 
[71] 
? 
 
Table 1: Genetic analysis of pendrin coding region in 58 deaf patients performed at the hospital of 
Campinas, Sao Paolo, Brazil; *: a mono allelic mutation (35delG) in the connexin-26 gene, GJB2, was 
also found; ?: non-characterized feature. 
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1.3.3 Subcellular localization and expression levels of   
 pendrin variants 
 
The functional characterization of pendrin variants is the key for determining the 
actual degree of impairment in the transport activity of mutated forms of the protein. Such 
knowledge is necessary for discriminating between protein variants with loss or reduction 
of function (mutations, potentially disease-causing) and variants with no functional 
impairment (benign polymorphisms).  
 
In order to define the actual molecular defect resulting in the experimentally 
determined degree of functional impairment, it is necessary to analyze further the specific 
mutant forms. The next step in the analysis and definition of the potentially pathogenic 
variants of pendrin is therefore the characterization of their specific molecular defect by 
determining their (i) subcellular localization and (ii) abundance in the cell.  
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Figure 5: Putative structure of pendrin showing the distribution of the mutations identified in the 
cohort of Brazilian deaf patients (Modified from: Dossena, S. et al. Journal of molecular 
endocrinology, 2009. 43:93-103). 
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A mutant isoform may undergo different destinies, according to the type of molecular 
defect. A specific mutation may:  
 
(I) determine a misfolding of the protein, preventing its correct trafficking to the 
plasma membrane (PM) and leading to its accumulation in an immature form 
in the endoplasmic reticulum (ER) and possibly to its degradation;  
(II) impair the transport activity per se without disrupting the correct folding and 
trafficking of the protein to the PM; this is the case of mutations affecting the 
ion binding sites. 
(III) interfere with the correct insertion of the polypeptide in the PM and/or its 
proper function, disrupting its interaction with other molecular entities, such as 
chaperones, cytoskeletal elements, regulatory proteins.  
 
The definition of the subcellular localization and abundance of the different pendrin 
variants, in combination with the related functional data, can deliver precious information 
regarding the specific type of molecular defect conferred by a specific aminoacidic 
substitution. Such knowledge can then drive the effort in the difficult challenge of 
investigating a possible mechanism for rescuing the transport activity of hypo-functional or 
non-functional proteins. Those mutants that are retained in the ER, may still be capable of 
an efficient ion transport if degradation is circumvented and/or folding is assisted 
pharmacologically. On the other side, mutants that show a partial trafficking to the plasma 
membrane may instead be potentiated in order to recover part of their transport activity. In 
the next chapters the “rescuing issue” and its possible approaches will be discussed more 
in detail. 
 
  1.3.4 Rescuing of pendrin activity 
 
Retention of the mutated forms of pendrin in the intracellular compartments is 
considered the main mechanism leading to the phenotype observed in many patients 
affected by syndromic and non-syndromic pendrin-related deafness [75]. Defective 
variants of pendrin cannot properly fold in the mature form of the transporter and are 
therefore retained in the ER, preventing their correct trafficking to the PM. The degradation 
of misfolded proteins mainly takes place in the complex called proteasome, where the 
defective polypeptide chain is chopped in small pieces by multiple enzymatic subunits 
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within the core of the complex [76]. An alternative pathway of degradation active in the cell 
involves the lysosomal enzymatic digestion [77]. This pathway is particularly active in 
degrading membrane proteins and phagocytized products but it also finds a role in the 
degradation of misfolded protein together with the proteasome complex. In this sense, for 
an effective modulation of the degradation/folding of mutant protein it is necessary to 
consider also this alternative pathway. 
 
The processing of newly synthesized proteins in the ER is driven through a number 
of checkpoints where the correct folding of the polypeptide is verified. Failure to pass any 
of the checkpoints leads to the arrest of the further maturation of the protein and activation 
of folding assisting mechanisms [76]. Accumulation of misfolded proteins in the ER 
induces the activation of a series of stress response mechanisms altogether termed the 
unfolded protein response (UPR), eventually leading to the activation of the ER associated 
degradation (ERAD) pathway [78]. In order to prevent excessive stress in the ER, different 
pathways can be activated. An ER-stress counteracting mechanism involves the 
expression of molecular chaperones in order to assist the correct and functional folding of 
the retained proteins [79]. The folding of a protein is assisted by a number of molecular 
chaperones along its pathway of maturation, activated according to the detected level of 
impairment. A second opportunity to reduce the ER stress is the stimulation of 
phospholipids synthesis and enlargement of the ER, necessary for the enhancement of its 
folding capacity [76, 80]. If the correct folding of the proteins accumulated in the ER is no 
more achievable or is too energy consuming, the misfolded polypeptide undergoes the 
poly-ubiquitination process, ultimately leading to the degradation in the 26S proteasome 
complex [76, 81]. Poly-ubiquitination of proteins is a three step process carried out by 
three different enzymes transferring ubiquitin molecules on specific residues on the 
polypeptide to be targeted to the proteasomal degradation. The first step of the process 
involves the activation of the ubiquitin molecule by a ubiquitin-activating-enzyme (E1) in an 
ATP-dependent fashion [82]. The activated ubiquitin molecule is then bound by a ubiquitin-
conjugating enzyme (E2) also called ubiquitin-carrier enzyme. E2 enzymes are 
responsible for transferring the ubiquitin molecule to the target protein, and finally, together 
with ubiquitin-ligase enzymes (E3), covalently bind the activated ubiquitin to a lysine of the 
polypeptide to be degraded. Many different E3 enzymes have been identified, with a high 
specificity for different target proteins, whereas much fewer different E2 enzymes and still 
fewer E1 enzymes have been identified in genome-wide analysis [83]. Ultimately, if the 
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accumulation of misfolded proteins and the correlated ER stress cannot be overcome and 
reduced by any of the mentioned mechanisms, the overproduction of reactive oxygen 
species (ROS) resulting from the ER forced hyperactivity leads to the activation of the final 
rescue mechanism, namely the apoptotic cell death, in order to prevent any further 
damage to the system [76, 84]. Defective and mutant proteins are often misfolded and 
retained in the ER lumen, triggering all of the above mentioned stress response 
mechanisms, and ultimately targeted for degradation. Ameliorating specific folding 
mechanisms and/or circumventing protein degradation may be the key for a targeted 
functional recovery of the activity of a protein of interest. 
 
The possibility to rescue the activity of pendrin hypo-functional and non-functional 
mutants has been considered and explored so far only in a small number of studies [85, 
86]. Ishihara et al. managed to rescue the trafficking to the PM and a partial ion transport 
activity of 4 pendrin mutants (P123S, M147V, S657Y and H723R) by treatment with 10 
mM salicylate [85]. The ability of salicylate to influence protein folding and maturation had 
been previously shown with regard to a paralogue of pendrin, SLC26A5 or prestin [87]. 
The same treatment was shown to be ineffective on the surface expression and activity of 
other 4 pendrin mutants (A372V, N392Y, S666F and T721M). Yoon et al. have shown the 
efficient recovery of Cl-/HCO3- exchange activity and protein abundance at the PM of 
pendrin H723R after incubation of transfected cells at low temperature and treatment with 
the histone deacetylase inhibitor Na+-butyrate. In this study, the same approach was 
applied to another pendrin mutant variant, namely L236P, but neither functional nor 
molecular rescue could be observed [86]. Both studies clearly showed the heterogeneity in 
the processing of the different mutant forms of pendrin and their unique behavior. Such 
heterogeneity observed at the functional and molecular level reflects the high variability of 
phenotype severity observed in deaf patients displaying different mutant variants of 
pendrin. This heterogeneity may not allow for a unique approach toward a possible rescue 
of the transport activity of different pendrin mutants.  
 
In that light, the functional and molecular characterization of defective pendrin allelic 
variants identified in the deaf population is a crucial piece of information in the view of a 
possible therapeutic approach against deafness caused by absent or reduced transport 
function of pendrin. In particular, the identification of mutant variants per se functional but 
mostly retained in the ER and eventually degraded results particularly interesting in driving 
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a possible therapeutical approach toward the inhibition of the degradation pathway and the 
assistance of proper folding. 
 
  1.3.5 Other genetic and molecular determinants of   
  deafness 
 
In 7 patients from the cohort subject of the study, deafness was reported in 
association to monoallelic pendrin mutations (Table 1). In these cases, monoallelic pendrin 
mutations may or may not be enough for determining deafness and other genetic defects 
or environmental factors may be involved in the development of deafness. 
 
The hearing loss phenotype may be related to a possible double heterozygosity, a 
condition where monoallelic pendrin mutations are found in combination with monoallelic 
mutations in other genes known to be involved in the sensory defect, such as the pendrin 
transcription factor FOXI1 or the potassium channel KCNJ10 [88, 89]. In the cohort of deaf 
patients analyzed in the present study, both FOXI1 and KCNJ10 genes have been 
sequenced and have been found in the wild type form, therefore excluding their role in 
determining deafness in this particular cohort. It is as well possible that mutations within 
the pendrin promoter region, or the 3’ untranslated region may influence the expression of 
the protein and therefore contribute to the development of the diagnosed phenotype. 
 
It is common opinion that it is necessary a bi-allelic pendrin mutation in order to 
observe the full spectrum of hearing defects characteristic of Pendred syndrome. 
Nonetheless, many reported cases are characterized by a severe deafness phenotype 
associated with monoallelic pendrin mutations [53, 67]. In some cases the determining 
cause of the observed degree of deafness may be due to other genetic or environmental 
factors, as discussed in the previous section.  
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 1.4 Functional screening of pendrin ligands 
 
  1.4.1 Role of pendrin overexpression and hyper-activity  
   and the need for a specific inhibitor 
 
As mentioned in the previous sections, deregulation of pendrin activity is associated 
with different pathological states, not only in the case of a loss or reduction of the transport 
function but also in those situation characterized by an over-expression and over-function 
of the transporter. In this regard, multiple studies in the last decade have shown that an 
increased expression and/or activity of pendrin may be associated with a number of 
pathologies, ranging from hypertension [29] to airway distresses such as asthma and 
COPD [40, 90]. 
 
Even though no correlation between pendrin mutations with gain of function and 
development of a hypertensive phenotype could be determined so far, the involvement of 
pendrin in the salt reabsorption in the distal section of the nephron has been shown in a 
number of studies [4, 13, 91].  
 
In the kidney, the transporter is mainly expressed in the distal convoluted tubule 
(DCT), in the connecting tubule (CNT) and in the apical membrane of beta- and non-α-
non-β-intercalated cells of the collecting duct (CD), where it has been shown to participate 
in the Cl-/HCO3- exchange [4]. Pendrin exchange activity contributes therefore to the 
regulation of systemic pH on one side, and to the reabsorption of Cl- on the other. Royaux 
et al. demonstrated pendrin being the major responsible for Cl- reabsorption in the distal 
section of the nephron and in particular in the CD [92]. Cl- reabsorption in the beta-
intercalated cells of the CD is coupled to the reabsorption of Na+ in the principal cells via 
ENaC, or via an alternative transporter [93], resulting in the movement of NaCl from the 
urine to the blood, followed by water, therefore regulating fluid volume and ultimately blood 
pressure [94]. The expression of pendrin in the kidney has been shown to be upregulated 
by aldosterone analogues [11] and angiotensin II [95]. Pendrin involvement in fluid volume 
homeostasis in the kidney is further supported by the observation that pendrin knock-out 
mice, even if not showing any abnormality at the basal state, submitted to NaCl restriction 
result in a severe Cl- wasting phenotype and development of hypotension [33]. 
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Furthermore, the same mice, treated with the aldosterone analogue 
deoxycocorticosterone pivalate (DOCP), developed metabolic alkalosis due to a complete 
lack of HCO3- secretion and resulted protected against aldosterone analogue-induced 
hypertension. In the same study it was shown that a moderate NaCl restriction is 
associated with an increase in pendrin expression at the apical side of beta-intercalated 
cells in the CD, probably as a compensatory mechanism. Increased chloride reabsorption 
associated with an increased pendrin expression in the distal section of the nephron could 
also be directly or indirectly coupled to an increased sodium reabsorption via other 
transporters or channels [11]. Supporting this hypothesis, Kim et al. have shown that lack 
of pendrin expression is associated with a decrease in the expression level of ENaC upon 
aldosterone stimulation, possibly due to the alkalosis resulting from the absence of 
pendrin-dependent HCO3- secretion [94], thus further supporting pendrin crucial role in 
NaCl reabsorption and blood pressure regulation. 
 
In the airways, an increased expression of pendrin at the bronchial level possibly 
contributes to the development and exacerbation of symptoms of asthma and COPD [5]. 
An abnormal Cl-/HCO3- transport activity is associated with an increase in chloride 
reabsorption followed by water. Pendrin hyperactivity leads therefore to a reduction in 
airway surface liquid (ASL) thickness and fluidity as the consequence of the increased 
water reabsorption [96]. A separate study shows that pendrin overexpression is associated 
with an increased mucus production [90] (Figure 6). The reduction of ASL thickness and 
the increase in mucus production may in turn exacerbate the symptoms of asthma as well 
as the diffusion of the inflammatory state and bacterial infections.  
 
On the other side, pendrin has been shown to contribute to the transport of 
thiocyanate into the ASL [34]. In the presence of hydrogen peroxide (H2O2), generated by 
the dual NAPDH oxidase (DUOX), thiocyanate is then oxidize to hypothiocyanate, known 
to exert an antimicrobial action (Figure 6). The expression of pendrin in the airways is 
regulated by stimulation with pro-inflammatory cytokines, and in particular by the action of 
interleukins 4 and 13 via the STAT-6 transcription regulation pathway [12, 34, 40].  
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In addition to an increased expression, also an increased intrinsic activity may lead to 
pendrin hyper-function. Indeed, gain of function mutations (i.e. showing and enhanced ion 
transport activity) of pendrin have been recently identified [71]. The existence of such 
hyper-functional forms of the transporter may be linked to the development of the 
pathological states just described. 
 
The need for a specific inhibitor becomes therefore clear when facing such 
pathological issues linked to a hyper-function/overexpression of the transporter. Pendrin 
constitutes a potential key target for the treatment of common pathological conditions such 
as bronchial asthma and hypertension, and the identification of a specific inhibitor is 
becoming a pressing issue. Some compounds showing an inhibitory effect on pendrin 
activity have indeed been identified but none of them is specific [97, 98].  
Figure 6: Pendrin in the airways. The expression of pendrin in the airways is stimulated by the 
pro-inflammatory cytokines IL-4 and IL-13. An increase in the transport activity of pendrin 
leads to the reduction of airway surface liquid thickness and increase mucus production. On 
the other side, pendrin is also responsible for the transport of thyocianate into the ASL. 
Thyocianate is then oxidized by H2O2 produced by DUOX, to produce the anti-microbic 
hypothiacyanate (Nofziger, C. et al. Cellular Physiology and Biochemistry, 2011. 28:571-578). 
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One of the goals of my research activity is the identification and characterization of 
new inhibitors of pendrin by functional screening of different compounds, selected among 
(i) substances with known inhibitory activity on transporters evolutionarily related to 
pendrin as well as (ii) diuretics and anti-hypertensive agents and (iii) small ligand 
molecules predicted via informatics tools (described more in detail in the following section). 
Possible side effects of a pendrin inhibitor on the inner ear, which would theoretically lead 
to hearing damages similar to those observed in Pendred patients, can be excluded since 
the role of the transporter seems to be limited to the completion of organogenesis of the 
hearing system [18], while an essential function later in the development has not been 
proven. Even though these results have been shown in mice pups, it is reasonable to 
imagine a similar situation in humans.  
 
  
  1.4.2 Selection of putative pendrin ligands for the   
   functional  screening 
 
The role of pendrin in the maintenance of ionic homeostasis in different biological 
compartments and its involvement in a number of pathologies suggests that this protein 
may be regarded to as an interesting and novel pharmacological target for different 
diseases. So far, no specific pendrin inhibitor or modulator could be identified, and even a 
high throughput screening of a large library of compounds failed in identifying new ligands 
for the transporter [34]. As mentioned in the previous section, few active compounds have 
indeed been identified, but none of them is specific for pendrin, and for some of them the 
actual efficacy is matter of debate. In particular, 4,4’-Diisothiocyano-2.2’-stilbenedisulfonic 
acid (DIDS), furosemide and probenecid at the concentration of 1 mM have been shown to 
inhibit the activity of the transporter both when expressed in Xenopus laevis oocytes [99], 
and in HEK 293 cells [100]. Evidences of an inhibitory activity of 5-Nitro-2-(3-
phenylamino)benzoic acid (NPPB) and niflumic acid have been shown in Human 
Embryonic Kidney (HEK) 293 Phoenix cells [97]. 
 
The search for pendrin ligands aims to the identification of chemical compounds 
(both inhibitors and activators/enhancers) capable of modulating the activity of the 
transporter. Inhibitors of pendrin activity may be an extremely useful therapeutic approach 
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for controlling hypertension and exacerbations of asthma and other respiratory distresses. 
On the other hand, an activator of pendrin activity may help developing a therapy 
circumventing or reducing hearing loss and/or thyroid dysfunction in patients with pendrin 
mutations. 
 
The functional screening of putative pendrin ligands can be efficiently carried out with 
the fluorometric method developed by Dossena et al. in 2006 and adapted for the use with 
a 96 well plate reader [69, 71, 101] (see Methods section for further details). As already 
mentioned, high-throughput screenings of large libraries of chemicals failed in identifying 
new pendrin inhibitors [34]. Our approach is therefore a more focused one, and requires a 
preliminary careful selection of a relatively small number of candidate compounds to be 
tested for their effect on pendrin activity in vitro.   
 
The selected compounds were classified, according to the rationale driving their 
choice for the screening, into three different groups: 
 
•  a first group includes known inhibitors of anion exchangers or channels, 
including substances with a known effect on homologues of pendrin, in particular 
inhibitors of Slc26a3, also known as downregulated in adenoma (DRA); 
 
•  a second group includes more or less commonly used antihypertensive and 
diuretic agents. This choice was driven by the evidence that pendrin plays a crucial 
role in the regulation of blood pressure in the kidney;   
 
•  a third group of compounds emerges from a different rationale; candidates in 
this group have been identified by means of a bioinformatics approach called meta-
analysis (described more in detail in the following section). This bioinformatics 
approach has been set up and delivered to us by Prof. R. Konrat, from the institute 
of Biochemistry & Biophysics, Structural & Computational Biology, University of 
Vienna (Austria). 
 
In the following sections the individual groups of compounds selected for the screening are 
discussed more in detail. 
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  1.4.2.1 Inhibitors of anion exchangers and anion  
     channels 
 
The closest homologue of pendrin is a member of the same SLC26 transporter 
family, namely Slc26a3, also known as DRA. The two proteins show a 44% of identity and 
a 60% of similarity. 
 
DRA is an anion exchanger responsible for the transport of Cl- and bicarbonate, as 
well as sulfate and oxalate. It is mainly expressed in the apical side of enterocytes of the 
proximal section of the colon [102] and in the duodenum [103], where it contributes to fluid 
reabsorption by mediating Cl-/Cl- and Cl-/HCO3- exchange [104]. A loss of transporter 
function leads to congenital chloride-losing-diarrhea (CLD), characterized by loss of a 
large amount of fluid in the stool and disruption of the intestinal mucosa adherence [105]. 
Chernova et al. characterized the pharmacological profile of DRA identifying the inhibitory 
effect, among others, of two anti-inflammatory drugs, namely niflumic acid and tenidap. 
Both drugs are known to lower the intracellular pH (lowering the intracellular pH may inhibit 
the bicarbonate secretion per se), but it could be shown, especially for what concerns 
tenidap, that the inhibitory effect is independent from the acidification of the cytosolic 
environment [106]. In a different study, Lamprecht et al. showed that the anti-diabetic drug 
glibenclamide was also effective in reducing the Cl- transport activity of DRA in Caco-2 
cells [107]. Even if the two transporters, DRA and pendrin, show a different ion selectivity, 
(DRA is capable of transporting both monovalent and divalent anions while pendrin only 
monovalent anions) their relatively high sequence similarity allows for the speculation of a 
possible common pharmacological profile.  
 
Other unselective inhibitors of anion exchangers and anion channels have been 
included in the screening, such as the anion exchanger blocker DIDS, the cystic fibrosis 
transmembrane conductance regulator (CFTR) inhibitor 172 (CFTR inh-172) and the 
chloride channel blocker 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB).  
 
Some of the tested compounds have already been tested on pendrin at different 
concentration [35], but were nonetheless included in the present study. 
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  1.4.2.2 Diuretic and antihypertensive agents 
 
The role played by pendrin in salt reabsorption and blood pressure regulation in the 
kidney candidates the transporter as a possible novel target for diuretic and anti-
hypertensive therapy. Also, the observed effect of some known diuretic agents may be 
due, at least partially, to an inhibitory effect on pendrin transport activity. For instance, a 
thiazide-sensitive NaCl reabsorption is still present in Na+-Cl--cotransporter (NCC) knock-
out mice [93] and may be due to pendrin. It is therefore not to be excluded that common 
diuretic and antihypertensive agents may modulate pendrin in addition to the classical 
target. Including diuretics in the functional screening may deliver precious information 
regarding the contribution of pendrin in blood pressure regulation and add novel 
information on the mechanism of action of known diuretics. Common diuretic and 
antihypertensive agents act by blocking transepithelial ion transport in the nephron, 
reducing therefore the consequent water movement from the urine into the bloodstream. 
This results in a decrease in plasma volume and blood pressure and, on the other side, in 
an increase of urine volume (diuresis).  
 
Typical diuretic agents used in the treatment of hypertension are:  
 
i) the thiazides, acting on ion transport in the DCT;  
ii) aldosterone and vasopressin antagonists, reducing NaCl reabsorption in the 
CD;  
iii) acetazolamide, reducing NaCl reabsorption in the proximal tubule; 
iv) the so called loop diuretics (furosemide, bumetanide), acting on the ion 
transport mainly in the thick ascending limb of the loop of Henle [108, 109]. 
 
The known molecular targets of the mentioned diuretic agents are, respectively: 
 
i) the Na+-Cl--cotransporter (NCC) in the DCT;  
ii) the epithelial Na+ channel (ENaC) in the CD; 
iii) the enzyme carbonic anhydrase and, indirectly, the Na+/H+ exchanger; 
iv) the Na+-K+-2Cl- cotransporter 2 (NKCC2) in the thick ascending limb of the 
Henle loop [110]. 
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  1.4.2.3 Protein meta-structure similarity clustering 
 
 The identification of putative ligands for a target protein often makes use of 
bioinformatics approaches and in particular of alignment algorithms aimed to the definition 
of similarity clusters of proteins sharing significant sequence/structural patterns. Proteins 
showing a significant aminoacidic sequence or structural similarity are often also sharing 
affinity for common ligands and interaction partners [111]. 
 
Most classical alignment approaches are based on the primary aminoacidic 
sequence of a protein in order to identify homology with other polypeptides. The risk in 
primary sequence alignment is the loss of potentially interesting partners that do not share 
a similar aminoacidic sequence but whose three-dimensional organization may still have a 
significant homology. In this view, one of the most established trends in similarity analysis 
nowadays is focusing on protein similarities on a structural level. Based on the observation 
that structural motifs are more conserved than primary amino-acidic sequences, the 
alignment of three-dimensional structures promises to be extremely useful when looking 
for similarities between proteins, in particular concerning the issue of ligand discovery. It 
has been shown that proteins sharing a similar 3D structure or similar domains often also 
share affinity for the same ligands [111]. Such a structural approach requires the definition 
of the three-dimensional structure of the protein of interest in order to be aligned with a 
database of structurally characterized proteins. Unfortunately, in many cases an 
experimentally defined structure is not available, especially when working with membrane 
proteins as pendrin. Due to their intrinsic flexibility and instability in aqueous media, the 
most common methods for structural analysis, crystallography and nuclear magnetic 
resonance (NMR), are often inapplicable. Lacking a full-length three-dimensional structure 
of our protein of interest, it is impossible to perform a classical structural alignment in order 
to predict putative binding molecules on a structural basis. It is therefore necessary the 
elaboration of a suitable alternative approach, in order to circumvent the lack of a defined 
three-dimensional structure. A very promising alternative approach is the so-called meta-
analysis. 
 
Meta-analysis is a bioinformatic approach aimed to the definition of a protein 
topology based on its primary amino acid sequence, without any knowledge regarding the 
three-dimensional structure of the protein of interest [112]. In order to do so, the interaction 
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probability of any given pair of residues within the target protein is calculated according to 
the formula 𝜌 𝜃,𝐴,𝐵, 𝑙!" , where 𝜃 represent the shortest path length observed between 
the two residues, A and B define the characteristic of the two specific residues involved in 
the interaction and 𝑙!" is their distance on the primary aminoacidic sequence of the protein 
of interest. The probability formula is based on the analysis and extrapolation of structural 
information collected from a number of characterized protein templates, in particular it is 
derived from the observation of actual inter-residues interactions within structurally defined 
proteins from the protein data base (PDB). The collection of all the probability values 
calculated for any residue pair within the target protein results in a network of more or less 
probable intramolecular interactions. Such a collection allows for the prediction of a 
putative 3D-structure of the protein of interest. The algorithm delivers information 
regarding the compactness of domains and regions within the target protein, and the local 
organization in secondary structure elements (alpha-helices and beta-sheets). 
 
Defined compactness values vary from 0 upwards and deliver information regarding 
how exposed different portions of the polypeptide are expected to be in the global 3D 
arrangement of the protein, telling us whether they are expected to be buried within the 
core of the protein or more exposed to the surface and to the solvent. A high compactness 
value is typically associated with residues buried in the interior of the protein structure, 
whereas values close to 0 are typical of residues located in more exposed and flexible 
regions or even disordered regions of the protein (Figure 7b). A further information 
delivered by the calculated probability function is the local secondary structure 
organization of the protein. Considering only short distance interactions (lAB<5), the 
algorithm gives information regarding the local organization in alpha-helices, beta-sheets 
or disordered regions. Positive values of this function are typically associated with more 
compact structures, such as alpha helices, whereas negative values are typical for 
residues located in more relaxed and extended regions, typically beta-sheets 
conformations (Figure 7a). 
 
The meta-structure of a protein is defined as the combination of information 
regarding local secondary structure organization and residue compactness throughout the 
whole polypeptide.  
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The meta-structure is to be considered as a topological abstraction of the primary 
sequence of a protein into the most probable three dimensional organization to be 
expected for the polypeptide. Being an abstraction, and not an actual model, it is capable 
of delivering more detailed information than an actual 3D model, revealing information also 
regarding disordered regions. Such regions of a protein are often escaping the classical 
structural characterization techniques, such as crystallography and NMR, but, due to their 
intrinsic flexibility, may be essential for the characterization of a protein function. 
 
Similarly to what happens with primary sequence alignments or three-dimensional 
structure alignments, the calculated meta-structure of the protein of interest can then be 
aligned with meta-structures originating from characterized protein templates collected in a 
database. The alignment allows for the evaluation of the similarity between the target 
protein and subjects found in the database, thus creating protein clusters of similarity. As 
in the case of classical protein alignments, it is then possible to hypothesize that known 
ligands for the proteins within a similarity cluster may also display significant affinity for our 
query protein (Figure 8). 
Figure 7: meta structure and model of the PI3-kinase p85 N-terminal SH2 domain. a) diagram 
representing the calculated local secondary structure organization along the analyzed domain of 
the protein. b) compactness value calculated for each residue in the region. c) predicted model; 
blue and red fragments correspond to the predicted secondary structure according to 7a (Konrat, 
R. Cellular and molecular life science, 2009. 66:3625-39). 	  
a	  
b	  
c	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The creation of the so called protein meta-structure similarity clusters (PMSSC), 
according to the conservation of structural motifs among different proteins, does not only 
deliver precious information regarding the putative three-dimensional organization of the 
protein of interest, but it can also be exploited as a powerful tool in the systematic 
evaluation of protein-ligand interactions, when the target protein shares a ligand-binding 
motif with characterized templates, according to their calculated meta-structure. 
 
 
 
 
   1.4.2.4 Shannon Entropy Descriptor ligand sensing 
 
The identification of an active compound represents a starting point for obtaining 
other potential ligands/modulators of pendrin activity. In the classical drug discovery 
concept, a widely adopted approach is the chemical modification of an active compound in 
order to improve its properties, such as affinity for the target protein, potency or specificity. 
By means of combinatorial chemistry, it is then possible to produce a large number of new 
Figure 8: The definition of Protein Meta-Structure Similarity Clusters (PMSSC), similarly to what is 
commonly achieved with Protein Structure Similarity Clustering (PSSC), allows for the prediction 
of putative ligands of the target protein. The calculated meta structure takes the place of the 3D 
structure of a protein in case this is not available (Modified from: Konrat, R. Cellular and molecular 
life science, 2009. 66:3625-39). 
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compounds starting from the structure of the original ligand identified. In our approach we 
chose a conceptually different route, by exploiting a different bioinformatic tool in order to 
refine the search for the desired modulator of pendrin activity. The further step in the 
search for potential ligands and modulators of our protein of interest can be undertaken by 
aligning the structure of an experimentally identified ligand with a database of chemical 
compounds. To do this, it is necessary to univocally define and describe a small 
compound in a way that allows the meaningful comparison with other small molecules. 
This is made possible by a bioinformatic abstraction, as described in the following.  
 
Based on the so called Shannon Entropy Descriptor (SHED), it is possible to define 
and categorize the nature of a small compound according to the functional relationship of 
atoms within the molecule. SHED is an information science-derived chemical descriptor 
whose aim is the classification of small molecules in similarity clusters according to the 
distribution of atom-centered feature pairs [113]. This means that every atom of the 
molecule is identified and classified according to defined chemical features (e.g.: 
hydrophobic, aromatic, proton acceptor or donor, etc.). The probability that each possible 
pair of atom-centered features is found at a certain distance within the small compound is 
calculated. The result of the calculation delivers an entropy value for the specific feature 
pair within the molecule. The same calculation is performed for any given features pair. 
The collection of all the entropy values of the molecule gives the so-called SHED score or 
SHED profile of the compound [113]. SHED profiles are univocal descriptors of the specific 
small compound and, as such, they can be compared and aligned to a database in order 
to define similarities with other small molecules. Such an approach, conceptually similar to 
the abstraction delivered by meta-analysis, has been proven extremely efficient 
concerning both chemical similarity and pharmacological profiling of compounds of 
interest. In other words, it has been shown that molecules displaying similar SHED profiles 
are not only chemically similar but, more importantly, they often show similarity also in 
what concerns their pharmacological behavior. 
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2. Aims of the study 
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2.1 Functional and molecular characterization of pendrin   
  allelic variants  
 
The definition of the genetic causes of deafness is the starting point for possible 
intervention processes for the affected patient and the family. Pendrin is a major player in 
the etiology of syndromic and non-syndromic hereditary deafness. The high phenotypical 
variability of pendrin-related deafness and the high incidence of benign polymorphisms 
does not allow for a straightforward correlation of genotype and phenotype. A definition of 
the actual role of pendrin in specific cases of hearing loss is only possible after functional 
characterization of the detected allelic variants. 
 
Our first objective was the functional characterization of pendrin variants identified in 
a cohort of deaf patients at the General Hospital of Campinas, Sao Paolo, Brazil, in order 
to define the role of pendrin mutations in the diagnosed hearing loss phenotype. 
Furthermore, the present study will contribute to spread light on the incidence of pendrin-
related deafness in this specific population, so far poorly investigated. 
 
The phenotypical variability is also reflected in the difference in molecular 
processing of the mutant forms of pendrin. A further step in the characterization of the 
identified allelic variants consists in the definition of the type of molecular defect caused by 
the different mutations. For this purpose, we also analyzed the subcellular localization and 
the abundance of the different variants of pendrin, in order to discriminate between 
mutations affecting the folding and the trafficking and mutations directly affecting the 
transport activity.  
 
The information collected from the functional and molecular characterization of the 
mutations is the starting point for a possible pharmacological approach aimed to the 
rescue of their transport activity. Such a rescue may be achieved by interfering with the 
degradation of misfolded proteins and facilitating their folding and trafficking process. 
 
2.2 Functional screening of pendrin ligands  
 
Pendrin hyperactivity and/or overexpression is linked to pathological states such as 
bronchial asthma, COPD and hypertension. Blocking or modulating the activity of the 
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transporter may define a novel paradigm in the treatment of the abovementioned 
pathologies. So far no potent, specific and non-toxic inhibitors for pendrin could be 
identified and the screening of large compound libraries failed in delivering any positive 
results.  
 
Thanks to a fluorometric method developed by Dossena et al. in 2006, we were able 
to screen the effect of compounds on pendrin activity in a semi-high-throughput fashion. In 
the search of a possible ligand (inhibitor/modulator) of pendrin we used a focused 
approach, looking for possible candidate compounds among three groups of chemicals: 
 
• known inhibitors of chloride channels and transporters and inhibitors of 
transporters homolog to pendrin, such as Slc26a3 (DRA); 
• antihypertensive and diuretic agents; 
• small compounds predicted by a bioinformatic approach based on the 
abstraction of the primary aminoacidic sequence of pendrin, called meta-
analysis.  
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3. Methods 
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3.1 Functional assay for the Cl-/I- exchange activity of   
  pendrin 
 
The effect of selected compounds or mutations on the transport activity of pendrin 
has been investigated by means of a fluorometric method developed by Dossena et al. in 
2006. This assay was first set up for measurements on a single cell level with a confocal 
microscope [17, 22, 44, 69] and later modified for a higher throughput approach on a multi-
plate reader [6, 71, 101]. 
 
The functional test allows for the evaluation of pendrin activity by determining 
changes in the intracellular iodide concentration following exposure of cells to an 
extracellular milieu containing iodide. Being pendrin an iodide/chloride exchanger, in the 
presence of iodide in the extracellular solution it can lead to an iodide influx. Increases in 
the intracellular concentration of this anion are detected thanks to the specific sensitivity of 
a modified form of the enhanced yellow fluorescent protein EYFP (EYFP H148Q I152L). 
The two aminoacidic substitutions of this EYFP isoform confer an increased sensitivity to 
intracellular iodide with respect to chloride and other anions. Intracellular iodide quenches 
the fluorescence emitted by EYFP H148Q I152L [114], therefore giving an indication of 
pendrin activity. 
 
Human Embryonic Kidney (HEK) 293 Phoenix cells were seeded on black 96-well 
plates (137101, Nunclon Delta Surface, Nunc, Denmark) and transiently double-
transfected with a plasmid carrying the cDNA coding for EYFP H148Q I152L and a 
pTARGET plasmid carrying the cDNA coding for wild type or mutated pendrin or the 
pTARGET empty vector, as the control. The assay was performed 48-52 hours after 
transfection as described in the following. The cells were washed three times from the 
culture medium, bathed in 70 µl of a high chloride isotonic solution (see below for the 
composition) and the fluorescence emission of EYFP H148Q I152L was measured at a 
wavelength of 535 nm upon excitation at 485 nm (1 measurement/sec for 3 sec). 
Successively, 140 µl of a high iodide-containing isotonic solution (see below for the 
composition) were injected into the bath via an automatic liquid dispenser, increasing the 
extracellular concentration of iodide to 90 mM. Then, the fluorescence intensity was 
measured again (1 measurement/sec for 16 sec). In the presence of active pendrin, the 
extracellular iodide is exchanged with intracellular chloride, leading to an increased 
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intracellular iodide concentration and quenching of the fluorescence emitted by EYFP 
H148Q I152L. As previously mentioned, the level of activity of the transporter is 
proportional to the decrease in the intracellular fluorescence recorded after the injection of 
iodide into the extracellular solution. 
 
Cell fluorescence was measured with the VICTOR™ X3 Multilabel Plate Reader 
(2030, Perkin Elmer, Finland) equipped with a liquid dispenser and the following filters: 
excitation: F485 (excitation center wavelength (CWL): 485 nm, bandwidth: 14 nm), 
emission: F535 (emission CWL: 535 nm, bandwidth: 25 nm). Experiments were performed 
at room temperature. 
 
The solutions used for the assay were prepared as follows: 
 
Isotonic High Chloride Solution: 
  135 mM NaCl, 2 mM KCl, 20 mM HEPES, 1 mM CaCl2, 1 mM 
  MgCl2, 10 mM Glucose  
  pH=7.4 
  308 mOsm/KgH2O 
 
Isotonic High Iodide Solution: 
  135 mM NaI, 2 mM KCl, 20 mM HEPES, 1 mM CaCl2, 1 mM  
  MgCl2, 10 mM Glucose 
  pH=7.4 
  308 mOsm/KgH2O 
 
3.2 Plasmids 
 
pTARGET vector containing the cDNA encoding for wild type pendrin cloned from 
normal thyroid tissue (pTARGET PDS WT) was originally provided by Prof. P. Beck 
Peccoz, University of Milan, Italy, and encodes for human pendrin with an hexahistidine 
tag at the C-terminus. Pendrin mutants were obtained by site-directed mutagenesis on the 
pTARGET PDS WT vector as described below. These vectors were used for the functional 
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test. pEYFPN1 vector encoding for EYFP was from Clontech. H148Q an I152L mutations 
were obtained by site-directed mutagenesis [71].  
 
For co-localization studies and evaluation of pendrin total and plasma membrane 
expression levels by confocal microscopy, the sequence coding for wild type pendrin was 
subcloned in frame with the EYFP coding sequence in the pEYFPN1 vector (Clontech). 
Following transfection of this construct in cells, pendrin is translated with EYFP fused to 
the C-terminus (PDS-EYFP). The pECFPN1 vector used in the evaluation of pendrin 
plasma membrane expression levels by confocal microscopy encodes for the enhanced 
cyano fluorescent protein ECFP (Clontech). 
 
For western blot analysis, the hexahistidine tag fused at the C-terminus of pendrin 
had to be removed. The corresponding vector was obtained in house by site-directed 
deletion of the hexahistidine coding sequence of the original pTARGET PDS WT vector, 
and was named pTARGETΔHIS PDS WT. Pendrin mutants were obtained by site-directed 
mutagenesis on the pTARGETΔHIS PDS WT vector as described below. 
 
All plasmids were sequenced by Microsynth AG, Switzerland, with the following 
primers, spanning the whole pendrin cDNA insert in the plasmid (Table 3): 
 
RPDS 1R 5’ – TTCCATTGCTGCTGGATACG – 3’ 
RPDS 2R 5’ – GGAAAATGATGCAGCAGCCAGC – 3’ 
RPDS 2F 5’ – TGGGATCTGTTGTTCTGAGC – 3’ 
RPDS 3R 5’ – TTGCCATAGAAAATAGGACTGG – 3’ 
RPDS 4F 5’ – GAAGCATCCCTAGCACAGATA – 3’ 
98198F 5’ – TGTTAAATCCATCCCAAG – 3’ 
 
3.3 Cell Culture and Transfection 
 
HEK 293 Phoenix [115] (originally provided by Prof. D. Di Francesco, University of 
Milan, Italy) and HeLa cells (CCL-2, Cervical Adenocarcinoma, ATCC) were grown in 
Minimum Essential Medium Eagle, supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 10000 U/ml penicillin, 10 mg/ml streptomycin and 1 mM pyruvic acid, sodium 
Table 3: sequencing primers for pendrin cDNA. 
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salt. The cells were maintained in an incubator (HERAcell 150, Thermo, Germany) at 37°C 
in a 5% CO2, 95% air, 100% humidity atmosphere. The cells were kept sub-confluent and 
sub-cultured every second to third day.  
 
For the functional assay, HEK 293 Phoenix cells were seeded in black 96 well 
plates and transfected 16 hours later. A cell confluence of ~ 40% ensured optimal 
transfection yield. Transient transfection of cells was performed by calcium phosphate co-
precipitation. In this method, the negatively charged phosphates of plasmid DNA form 
complexes with the positively charged calcium ions in the transfection mix and are 
internalized by the cells. The formation of complexes masks the negative charge on the 
DNA that would otherwise prevent it from traversing the plasma membrane. 
 
The transfection mix for one row of 12 wells of a 96-well plate was prepared as 
follows: 
 
Wild type (WT) or mutant (MUT) pendrin: 
 pTARGET-PDS WT/MUT 3 µl (0.5 µg/µl) 
 pEYFP H148Q I152L 3 µl (0.5 µg/µl) 
20x CaCl2   7.5 µl 
 H2O    61.5 µl 
 2x HBS   75 µl 
 
Control: 
 pTARGET-EMPTY  3 µl (0.5 µg/µl) 
 pEYFPN1 H148Q I152L 3 µl (0.5 µg/µl) 
20x CaCl2   7.5 µl 
 H2O    61.5 µl 
 2x HBS   75 µl 
 
The transfection mix was incubated for 10 minutes at room temperature in order to 
allow for the complexes to be formed. After the incubation, 10 µl of transfection mix (i.e. 
0.1 µg of pTARGET-PDS WT/MUT plasmid and 0.1 µg pEYFP H148Q I152L plasmid) 
were carefully pipetted into each well.  
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For co-localization studies and evaluation of total pendrin expression levels by 
confocal microscopy, HeLa cells were seeded in 6 well plates and transfected for 72 h with 
1.5 µg of plasmid DNA encoding for wild type or mutant PDS-EYFP and 3 µl of 
Metafectene PRO®, following the manufacturer instructions. Media was changed 7-8 hours 
after transfection. 
 
For evaluation of plasma membrane pendrin expression levels by confocal 
microscopy, HeLa cells were seeded in 6 well plates and transfected for 72 h with 0.25 µg 
of plasmid DNA coding for ECFP (pECFPN1), 1.25 µg of plasmid DNA coding for wild type 
or mutant PDS-EYFP and 3 µl of Metafectene PRO®, following the manufacturer 
instructions. Media was changed 7-8 hours after transfection. 
 
For western blot analysis, HEK 293 Phoenix cells were seeded in 6 well plates and 
transfected for 72 hours with the calcium phosphate co-precipitation method as described 
above. Each well was transfected with 150 µl transfection mix, containing 2 µg of plasmid 
DNA coding for wild type or mutant pendrin. Media was changed 7-8 hours after 
transfection. 
 
Buffers and Solutions: 
 
 20x CaCl2Solution: 
  2.5 M 2H2OlCaCl2  
 
2x HEPES-buffered solution (HBS): 
  140 mM NaCl; 1.5 mM 2H2OlNa2HPO4, 50 mM HEPES,  
  pH=7.05  
 
 3.4 Site-directed mutagenesis 
 
The point mutations in the coding sequence of pendrin were obtained by site-
directed mutagenesis with the QuickChange® site-directed mutagenesis kit (200518, 
Stratagene, USA) according to the manufacturer’s instructions with the primer pairs 
indicated in Table 4: 
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P142L sense           5’- GTTGGACCTTTTCTAGTGGTGAGTTTAATGG -3’ antisense     5’- CCATTAAACTCACCACTAGAAAAGGTCCAAC -3’ 
G149R sense           5’- GAGTTTAATGGTGAGATCTGTTGTTCTGAGC -3’ antisense     5’- GCTCAGAACAACAGATCTCACCATTAAACTC -3’ 
T193I sense           5’- GCCAGTGCCCTGATTCTGCTGGTTGG -3’ antisense     5’- CCAACCAGCAGAATCAGGGCACTGGC -3’ 
C282Y sense           5’- CACCATTGTCGTCTATATGGCAGTTAAGG -3’ antisense     5’- CCTTAACTGCCATATAGACGACAATGGTG-3’ 
Q413R sense           5’- CCCGCACGGCCGTCCGGGAGAGCACTGGAGG -3’ antisense     5’- CCTCCAGTGCTCTCCCGGACGGCCGTGCGGG -3’ 
L445W sense           5’- GCTTCTGGAACCCTGGCAGAAGTCGGTCTTGGC -3’ antisense     5’- GCCAAGACCGACTTCTGCCAGGGTTCCAGAAGC -3’ 
R776C sense           5’- CCAGGATGAGGCTATGTGTACACTTGCATCC -3’ antisense     5’- GGATGCAAGTGTACACATAGCCTCATCCTGG -3’ 
E29Q sense           5’-GCCGGTCTACAGCCAGCTCGCTTTCCAG-3’ antisense     5’-TGGAAAGCGAGCTGGCTGTAGACCGGC-3’ 
P140H sense           5’-CAAGACATATCTCAGTTGGACATTTTCCAGTGGTGAGTTTAAT-3’ antisense     5’-ATTAAACTCACCACTGGAAAATGTCCAACTGAGATATGTCTTG-3’ 
Q413P sense          5’-GCACGGCCGTCCCGGAGAGCACTGG-3’ antisense    5’-CCAGTGCTCTCCGGGACGGCCGTGC-3’ 
G424D sense          5’-AAGACACAGGTTGCTGACATCATCTCTGCTGCG-3’ antisense    5’-CGCAGCAGAGATGATGTCAGCAACCTGTGTCTTTC-3’ 
T485R sense          5’-TTGATGCTGTTATCTGGGTGTTTAGGTGTATAGTGTCC-3’ antisense    5’-GGACACTATACACCTAAACACCCAGATAACAGCATCAATC-3’ 
Q514K sense          5’-GACTGTGGTCCTGAGAGTTAAGTTTCCTTCTTGGA-3’ antisense    5’-TCCAAGAAGGAAACTTAACTCTCAGGACCACAGTC-3’ 
D724G sense          5’-CATTCTTTTTGACGGTCCATGGTGCTATACTCTATCTACAGAA-3’ antisense    5’-TTCTGTAGATAGAGTATAGCACCATGGACCGTCAAAAAGAATG-3’ 
  
 
All oligonucleotide primers were purchased from Microsynth (Balgach, Switzerland). 
  
 3.5 Screening of pendrin ligands 
 
The substances selected for the screening were purchased either from Sigma-
Aldrich, USA, Fluka, Germany or SIA MolPort, Latvia. According to the indication of the 
vendor, each substance was resuspended in the suitable solvent (dimethyl sulfoxide 
(DMSO), absolute ethanol or polyethylene glycol 400, Table 5). For each substance, a 
Table 4: Mutagenesis primers for inserting the indicated aminoacidic substitution in pendrin sequence. 
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stock solution was prepared and stored at -20°C. The working dilution for the assay was 
100 µM in high chloride and high iodide isotonic solution for all the substances, except 
when otherwise specified. 
 
Substance CAS number Stock Catalog number, Vendor 
NB (5-nitro-2-(3-
Phenypropylamino)benzoic acid)  107254-86-4 
300 mM in 
DMSO N4779, Sigma-Aldrich, USA 
DIDS (4,4’-diisothiocyanatostilbene-
2,2’-disulfonic acid) 207233-90-7 
300 mM in 
DMSO 
D3514, Sigma-Aldrich, USA 
  
CFTR inhibitor – 172 307510-92-5 5 mM in DMSO C2992, Sigma-Aldrich, USA 
DNDS (4’,4’-dinitrostilbene-2,2’- 
disulfonic acid) 128-42-7 
300mM in 
isotonic sol. S347523,Sigma-Aldrich,USA 
Niflumic acid 4394-00-7 300 mM in DMSO N0630, Sigma-Aldrich, USA 
Tenidap 120210-48-2 300 mM in DMSO PZ0196, Sigma-Aldrich, USA 
Glybenclamide 10238-21-8 300 mM in DMSO G0639, Sigma-Aldrich, USA 
Probenecid 57-66-9 300 mM in chloroform  P8761, Sigma-Aldrich,USA 
Eplerenone 107724-20-9 30 mM in DMSO E6657, Sigma-Aldrich, USA 
Acetazolamide 59-66-5 300 mM in DMSO A6011, Sigma-Aldrich, USA 
Bumetanide 28395-03-1 300 mM in DMSO B3023, Sigma-Aldrich, USA 
Furosemide 54-31-9 300 mM in DMSO F4381, Sigma-Aldrich, USA 
Hydrochlorothiazide 58-93-5 300 mM in DMSO H4759, Sigma-Aldrich, USA 
Cholesterol 57-88-5 300 mM in chloroform C8667, Sigma-Aldrich, USA 
Iloprost (Ilomedin® - Bayer) -- -- Bayer Schering Pharma, Germany 
Vasopressin 113-79-1 3 mM in isotonic sol. V9879, Sigma-Aldrich, USA 
Vitamin D (Dihydrotachysterol) 67-96-9 300 mM in DMSO D9257, FLUKA, Germany 
Vitamin E (α-Tocopherol) 10191-41-0 300 mM in DMSO T3251, Sigma-Aldrich, USA 
(-)Nicotine 54-11-5 300 mM in isotonic sol. N3876, Sigma-Aldrich,USA 
N-(2-chlorophenyl)-2-(2,4-
dibromophenoxy)acetamide  not available 
300 mM in 
DMSO 002-045-764, MolPort, Latvia 
2-{[(2,3-dichlorophenyl)methyl]amino}-
1-phenylethanol not available 
300 mM in 
DMSO 000-938-685, MolPort, Latvia 
Naloxone 465-65-6 300 mM in DMSO 143005, FLUKA, Germany 
Tolcapone 134308-13-7 300 mM in DMSO 
SML0150, Sigma-Aldrich, 
USA 
Topiramate 97240-79-4 300 mM in DMSO T0575, Sigma-Aldrich, USA 
Colchicine 64-86-8 300 mM in ethanol C9754, Sigma-Aldrich, USA 
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Scopolamine 6533-68-2 300 mM in isotonic sol. S0929, Sigma-Aldrich, USA 
6-phenylamino nicotinic acid 13426-16-9 300 mM in DMSO 
CSD009518, Sigma-Aldrich, 
USA 
Levamisole 16595-80-5 300 mM in isotonic sol. L0380000, FLUKA, Germany 
Levallorphan 71-82-9 300 mM in isotonic sol. L121, Sigma-Aldrich, USA 
Ticlopidine 53885-35-1 300 mM in isotonic sol. T6654, FLUKA, Germany 
Flufenamic acid 530-78-9 300 mM in DMSO F9005, FLUKA, Germany  
    
 
 
 3.6 Subcellular localization of pendrin variants 
 
  3.6.1 Co-localization with the plasma membrane  
 
The staining of the plasma membrane was performed in vivo on HeLa cells with the 
CellMask™ Deep Red Plasma Membrane Stain (5 mg/ml stock solution in DMSO, C10045, 
Molecular Probes, USA). The Plasma Membrane Stain stock solution was diluted to 1.25 
µg/ml in Hank’s Balanced Salt Solution (HBSS).  
 
HeLa cells were seeded in 6 wells plates, grown to 40% confluence and transfected 
with wild type or mutant PDS-EYFP as described above. 56 hours after transfection, cells 
were resuspended by trypsinization and transferred on 3 cm diameter microscope slides. 
72 h after transfection, cells were washed three times with ice cold HBSS and incubated 
with 1.25 µg/ml CellMask Deep Red Plasma Membrane Staining Solution for 5 minutes on 
ice. The staining solution was then removed and cells were washed again three times with 
ice cold HBSS. Imaging was performed immediately after staining in cold HBSS using a 
Leica TCS SP5 II AOBS confocal microscope (Leica Microsystems, Germany), with a 63x 
PL APO Lambda blue water immersion objective (numerical aperture 1.2), a 514 nm Argon 
laser line for exciting EYFP (λex.: 514 nm, λem.: 525-600 nm) and a 633 nm HeNe laser 
line for exciting the Plasma Membrane Stain (λex.: 633 nm, λem.: 655-750 nm). 
 
The quantitative analysis of the co-localization between PDS-EYFP and the plasma 
membrane was performed by determining the Pearson’s coefficient of correlation of the 
Table 5: list of chemicals tested on pendrin activity with the fluorometric method. For each substance, the 
Chemical Abstracts Service (CAS) registry number, concentration and solvent of the stock solution, 
catalog number and vendor are specified. 
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two signals according to the formula 𝑅 = !!!!!!!"# ! !!!!!!!"#! !!!!!!!"# !! !!!!!!!"# !!  where 𝑆1!  and 𝑆2! 
represent the intensity of any i pixel respectively in the emission channel 1 and 2 while 𝑆1!"# and 𝑆2!"# represent the average intensity of all pixels respectively in the emission 
channel 1 and 2. A Pearson’s coefficient of 0 indicates a random correlation, whereas 
values close to +1 and -1 indicate co-localization and mutual exclusion of the two signals, 
respectively. Sequential acquisition and analysis of images were performed with the LAS 
AF SP5 software (Leica Microsystems, Germany). 
 
  3.6.2 Co-localization with the endoplasmic reticulum  
 
The staining of the endoplasmic reticulum was performed in vivo with ER-Tracker™ 
Red Glibenclamide BODIPY®-TR (E34251, Molecular Probes, USA). The dye was 
reconstituted in 110 µl DMSO to obtain a 1 mM stock solution and stored at -20°C. A 1 µM 
working dilution was obtained in Krebs-Henseleit Buffer (K3753, Sigma-Aldrich, USA). 
 
HeLa cells were seeded in 6 wells plates, grown to 40% confluence and transfected 
with wild type or mutant PDS-EYFP as described above. 56 hours after transfection, cells 
were resuspended by trypsinization and transferred on 3 cm diameter microscope slides. 
72 h after transfection, cells were washed three times with Krebs-Henseleit Buffer at room 
temperature and incubated with 1 µM ER-Tracker for 20 minutes at 37°C, 5% CO2. The 
staining solution was then removed and cells were washed with HBSS. Imaging was 
performed in HBSS immediately after staining using a Leica TCS SP5 II AOBS confocal 
microscope, with a 63x PL APO Lambda blue water immersion objective (numerical 
aperture 1.2), a 514 nm Argon laser line for exciting EYFP (λex.: 514 nm, λem.: 525-555 
nm) and a 561 nm DPSS laser line for exciting the ER-Tracker (λex.: 571 nm, λem.: 650 
nm). 
 
The quantitative analysis of the co-localization between the ER and PDS-EYFP 
signals was performed by determining the Pearson’s coefficient of correlation as described 
above. Sequential acquisition and analysis of images were performed with the LAS AF 
SP5 software (Leica Microsystems, Germany). 
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 3.7 Quantification of the expression levels of pendrin   
  variants 
 
Two complementary methodologies have been used in order to have a complete 
picture of the molecular fate of the different pendrin variants: imaging of EYFP-tagged 
proteins and western blot analysis of cellular protein extracts from transfected cells. 
 
   3.7.1  Fluorescence Imaging 
 
Cells for imaging experiments were transfected with the different variants of pendrin 
fused to EYFP (PDS-EYFP). Either the total or the plasma membrane expression of 
pendrin variants was evaluated by detecting the signal emitted by PDS-EYFP. 
 
   3.7.1.1 Total pendrin expression 
 
HeLa cells were seeded in 6 wells plates, grown to 40% confluence and transfected 
with WT or mutant PDS-EYFP as described above. 56 hours after transfection, cells were 
resuspended by trypsinization and transferred on 3 cm diameter microscope slides. 72 
hours after transfection, cells were washed in HBSS and fixed for 15 minutes with 4% 
paraformaldehyde. After fixation, cells were incubated for 10 minutes with 0.1 µg/ml 4’,6-
diamidino-2-phenylindole (DAPI, D9542, Sigma-Aldrich, USA) in HBSS. The nuclear 
staining with DAPI can give an indication of the number of cells in the imaged field and 
was necessary in order to normalize the PDS-EYFP signal for the cell density. Cells were 
imaged immediately after preparation with a Leica TCS SP5 II confocal microscope, 
equipped with a 63x PL APO Lambda blue water immersion objective, numerical aperture 
1.2, a 514 nm Argon laser line for exciting EYFP (λex.: 514 nm, λem.: 525-597 nm) and a 
405 nm diode laser for exciting DAPI (λex.: 405 nm, λem.: 430-470 nm). The signal 
emitted by PDS-EYFP in the whole field of imaging was expressed as averaged levels of 
grey and normalized by the signal emitted by DAPI in the same field, also expressed as 
averaged levels of grey. Imaging parameters (laser power, photomultiplier gain, pixel size 
and zoom factor) were kept rigorously constant for all the acquisitions. Subtraction of 
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background fluorescence was performed for all acquisitions in both EYFP and DAPI 
emission channels. 
 
   3.7.1.2 Plasma membrane pendrin expression 
 
For this set of experiments, a different normalization approach was set up, and 
considered the transfection efficiency of the single cell. HeLa cells were co-transfected as 
previously described with wild type or mutant PDS-EYFP and ECFP as an indicator of 
transfection efficiency of the single cell. The signal of PDS-EYFP in regions of interest of 
the plasma membrane (PM) of the selected cell, expressed as averaged levels of grey, 
was normalized for the emission of ECFP in the cytosol of the same cell, also expressed 
as averaged levels of grey. In order to clearly identify the PM, especially for those pendrin 
variants lacking a PM localization, cells were stained on ice with 1.25 µg/ml CellMask 
Deep Red Plasma Membrane Stain, as previously described. Imaging was performed in 
vivo immediately after staining with a Leica TCS SP5 II confocal microscope, equipped 
with a 63x PL APO Lambda blue water immersion objective, numerical aperture 1.2, a 514 
nm Argon laser line for exciting EYFP (λex.: 514 nm, λem.: 525-580 nm), a 405 nm diode 
laser line for exciting ECFP (λex.: 405 nm, λex.: 450-490 nm) and a 633 nm HeNe laser 
line for CellMask (λex.: 633 nm, λex.: 643-750 nm). Imaging parameters, such as laser 
power, photomultiplier gain, pixel size and zoom factor, were kept constant for all the 
acquisitions. Subtraction of background fluorescence was performed for all acquisition in 
both PDS-EYFP and ECFP emission channels. 
 
  3.7.2  Western Blot  
 
HEK 293 Phoenix cells for western blot were transfected with the pTARGET vector 
carrying the cDNA for wild type or mutant pendrin by the calcium phosphate co-
precipitation method, as described above. As previously mentioned, the exahistidine tag 
originally fused to the C-terminus of pendrin was removed for this set of experiments.  
 
   3.7.2.1 Total protein extraction 
 
72 hours after transfection, the cells and their culture medium were collected and 
centrifuged at 216 xg for 15 minutes at 4°C. The collected cell pellets were washed twice 
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with ice cold phosphate buffer saline (PBS) and lysed on ice in a denaturing lysis buffer 
(see below for the composition) supplemented with Halt Protease Inhibitor Single-use 
Cocktail.  
 
Cell lysates were centrifuged for 30 minutes at 17000 xg, 4°C, in order to precipitate 
the non-lysated/non-soluble fraction. The supernatant was collected into a fresh tube and 
the total protein content of each sample was determined by the Bradford assay (500-0006, 
Biorad, Germany), following the manufacturer instructions. About 60 µg of each total 
protein extract were loaded on the gel. 
 
Samples for Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) were prepared by adding a denaturing loading dye containing dithiothreitol (DTT) 
as a reducing agent and boiled for 5 minutes before loading in a 7.5% polyacrylamide gel. 
As a standard, 10 µl of Page Ruler Prestained Protein Ladder (26616, Thermo Scientific, 
USA) were loaded in the gel. The gel was run at constant voltage (120 V) for 2 hours at 
room temperature. Subsequently, the separated proteins were transferred on 
polyvinylidene difluoride (PVDF) membranes (Immunoblot PVDF Membranes, BIO-RAD, 
Germany) by applying a constant voltage (75 V) for 2 hours at 4°C. The membranes were 
blocked for 1 hour at room temperature in 5% nonfat dry milk in tris buffered saline and 
Tween (TBST, 0.1% Tween) and then incubated overnight at 4°C with the primary 
antibodies in 3% nonfat dry milk in PBS. After 3 washing steps in TBST, the membranes 
were incubated for 1 hour at room temperature with the infrared dye-conjugated secondary 
antibodies diluted in 3% nonfat dry milk in PBS. Finally, the membranes were washed 3 
times in TBST. Detection of the signal of immunocomplexes was performed with the 
ODYSSEY infrared imaging system (LI-COR, USA).  
 
Blot images were densitometrically analyzed with the ImageJ 1.46r software (Wayne 
Rasband, NIH, USA). The signal intensity of the bands corresponding to pendrin, 
expressed as levels of grey, was normalized on the signal intensity of the bands 
corresponding to the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), similarly expressed as levels of grey. 
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   3.7.2.2 Extraction of total cellular membranes proteins  
 
The extraction of the total membranes fraction, including both plasma membrane 
and membranes from cellular organelles, was performed with the Plasma Membrane 
Extraction Kit (JM-K268-50, MBL, USA), according to the manufacturer instructions. 
The cells were seeded and transfected as described above. 72 hours after 
transfection, the cells were collected by centrifugation. The pellet was washed twice in ice 
cold PBS and resuspended in Homogenizing Buffer from the above mentioned kit. Lysis 
was achieved using a syringe with a small gauge needle. Complete lysis was confirmed by 
the almost total absence of intact nuclei in the sample upon observation with a phase-
contrast inverted microscope (AE31, Motic	  GmbH, Germany). The lysate was centrifuged 
for 10 minutes at 700 xg, 4°C, in order to remove the non-lysate/non-soluble fraction but 
conserving the membranes fraction in the supernatant. The supernatant was centrifuged a 
second time at 10000 xg for 30 minutes, 4°C. The pellet from the second centrifugation 
step represents the total cellular membranes fraction, while the supernatant contains the 
soluble proteins fraction. Samples for the gel were prepared resuspending the protein 
pellet in loading dye containing DTT. Before loading on the gel, the sample were boiled for 
5 minutes. SDS-PAGE and western blotting were performed as described above. 
Detection of the signal of immunocomplexes was performed with the ODYSSEY infrared 
imaging system (LICOR, USA). 
Blot images were densitometrically analyzed with the ImageJ 1.46r software (Wayne 
Rasband, NIH, USA). The signal intensity (expressed as levels of grey) of the bands 
corresponding to pendrin was normalized on the signal intensity (expressed as levels of 
grey) of the bands corresponding to the housekeeping protein calreticulin.  
 
Buffers and Antibodies: 
 
 Denaturing Lysis Buffer (total proteins extraction) 
 50 mM Trizma base, 150 mM NaCl, 1% NP-40 alternative, 1% Halt Protease 
 Inhibitor Single-use Cocktail. 
  
 Loading dye 
 240 mM Trizma HCl pH 6.8, 40% Glycerol, 0.04% Bromophenol blue, 5% β-
 mercaptoethanol or 100 mM DTT, 8% SDS. 
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 Running Buffer 
 25 mM Trizma base, 144 mM Glycine, 1% SDS.  
 
 Transfer Buffer 
 27 mM Trizma base, 190 mM Glycine. 
 
  
 Wash Buffer 
 40 mM Trizma base, 270 mM NaCl, 0.1% Tween20. 
 pH=7.5 
 
 Primary antibodies: 
 
  Anti-PDS: rabbit anti-pendrin antibody against the C-terminal domain 
  of human pendrin (kindly provided by Prof. Dominique Eladari, Paris,  
  France).  
  Working dilution 1:10000. 
 
  Anti-GAPDH: goat anti-GAPDH antibody (A00191-100, GenScript). 
  Working dilution 1:1000.    
 
  Anti-Calreticulin: rabbit anti-Calreticulin antibody (ab4, abcam). 
  Working dilution 1:1000  
 
 Secondary antibodies: 
 
  Goat anti-Rabbit IRDye 800CW Conjugated (LI-COR). 
  Working dilution 1:20000  
 
  Donkey anti-Goat IRDye 800CW Conjugated (LI-COR). 
  Working dilution 1:20000  
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3.8 Rescuing of pendrin activity 
 
The study of a possible functional rescue of pendrin upon treatment with a 
proteasome inhibitor was performed by means of the same functional test described 
above. For this aim, HEK 293 Phoenix cells were transfected as described earlier with the 
different pendrin variants. 48 hours after transfection, cells were incubated for 6 hours in 
complete media supplemented with the proteasome inhibitor MG132, 10 µM (C2211, 
Sigma-Aldrich, USA), or its vehicle (0.1% DMSO). Before measurements, cells were 
washed three times and bathed in high chloride solution. The functional test was 
performed as described earlier. 
 
For the imaging experiments, HeLa cells were seeded in 6 wells plates, grown to 
40% confluence and transfected with wild type or mutant PDS-EYFP as described above. 
36 hours after transfection, cells were resuspended by trypsinization and transferred on 3 
cm diameter microscope slides. 60 hours after transfection, the proteasome inhibitor 
MG132, 10 µM, or its vehicle (0.1% DMSO) were added to the media and cells were 
grown overnight in the incubator. 72 hours after transfection, cells were prepared for the 
imaging according to the respective protocols for total and plasma membrane pendrin 
evaluation, as described above. 
 
3.9 Statistical analysis 
 
Statistical analyses for all data sets presented in this thesis were performed with 
GraphPad Prism version 5.0b for MAC (GraphPad Software, San Diego, California, USA).  
 
Data are expressed as mean values ± standard error of the mean (SEM). n 
corresponds to the number of independent measurements. Statistical differences between 
data sets were verified by the one-way analysis of variance (ANOVA) followed by 
Bonferroni’s multiple comparison or Dunnett’s post-tests or by the unpaired Student’s t-
test, as appropriated. Differences were considered statistically significant when the p value 
was ≤ 0.05. 
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 3.10 Salts and Reagents: 
 
All salts and reagents were of pro-analysis grade quality. 
 
Minimum Essential Medium Eagle (M5650, Sigma, Austria) 
Fetal Bovine Serum (DE14-801F, Lonza, USA) 
L-glutamine (G7513, Sigma-Aldrich, USA) 
Penicillin, Streptomycin (P0781, Sigma-Aldrich, USA)  
Pyruvic acid, sodium salt (P2256, Sigma-Aldrich, USA) 
Metafectene PRO® (T040, Biontex, Germany) 
DMSO (D2650, Sigma-Aldrich, USA) 
Ethanol absolute (1.07017.2511, Merk, Germany)  
Polyethylene glycol 400 (202398, Sigma-Aldrich, USA) 
HBSS ( H1387, Sigma-Aldrich, USA) 
NaCl (A4256, Applichem, Germany) 
KCl (P5405, Sigma-Aldrich, USA) 
HEPES (A3268, Applichem, Germany) 
CaCl2 (21114, Fluka, Germany)  
MgCl2 (A4998, Applichem, Germany) 
Glucose (49139, Sigma-Aldrich, USA) 
NaI (040196, AlfaAesar, Germany) 
2H2OlCaCl2 (172570,Merck, Germany) 
2H2OlNa2HPO4 (71649, Fluka, Germany ) 
Trizma base (T1503, Sigma-Aldrich, USA) 
NP-40 alternative (492016, Calbiochem, Germany) 
Halt Protease Inhibitor Single-use Cocktail (1860932, Thermo Scientific, USA) 
Trizma HCl pH 6.8 (T5941, Sigma-Aldrich, USA) 
Glycerol (A16205, AlfaAesar, Germany) 
Bromophenol blue (A18469, AlfaAesar, Germany) 
β-mercaptoethanol (M6250, Sigma-Aldrich, USA)  
DTT (443852A, VWR, England) 
SDS (444464T, VWR, England) 
Glycine (G8898, Sigma-Aldrich, USA) 
Tween 20 (437082Q, VWR, England) 
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4. Results 
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 4.1 Functional characterization of pendrin allelic variants  
 identified in a cohort of Brazilian deaf patients 
 
Disclaimer: the functional studies were performed in our laboratories at the Paracelsus Medical University, 
Salzburg, in collaboration with the University of Campinas, Brazil. I have participated in performing and 
analyzing all of the experiments described in this section.  
 
Seven of the pendrin allelic variants identified in the genetic screening of a cohort of 
58 deaf Brazilian patients, performed by our collaborators at the University of Campinas, 
Sao Paolo, Brazil (see Introduction, Table 1), were functionally characterized with the 
fluorometric method developed by Dossena et al. in 2006 and described in the Methods 
section. The 3 novel pendrin variants identified in this cohort (P142L, G149R [66] and 
C282Y) along with 3 known but functionally uncharacterized pendrin variants (L445W, 
Q413R and T193I) were included in the functional test. A further allelic variant (R776C) 
was also tested, even though it had already been characterized, because results were 
controversial [67, 68]. 
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Figure 9: Functional test of pendrin allelic variants identified in Brazilian deaf patients with or 
without EVA. a) novel mutations; b) mutations already reported in the literature but not yet 
characterized on a functional level, or whose characterization was ambiguous. HEK 293 Phoenix 
cells were co-transfected with wild type or mutated pendrin and EYFP H148Q I152L, or with EYFP 
H148Q I152L alone (control). Black bars indicate complete loss of function, grey bars a reduction 
of function, white bars represent the wild type and unaffected function. n was 42 in a) and 70 in b). 
n.s. not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one way ANOVA with 
Bonferroni’s post-test. 
 
a)	   b)	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In Figure 9, the % decrease in intracellular EYFP H148Q I152L fluorescence after 
addition of iodide to the extracellular solution is shown for all the different pendrin allelic 
variants analyzed. The decrease in intracellular fluorescence is the consequence of an 
iodide influx and is therefore indicative of the level of transport activity of wild type or 
mutated pendrin (see Methods for further details). The transport activity measured for the 
different pendrin allelic variants was statistically compared to the activity of the wild type 
and the control (cells expressing EYFP H148Q I152L only and no pendrin). 
 
The functional tests were performed in two separated groups for technical 
convenience, as it is essential that pendrin variants are tested on the same 96 well plate 
as the wild type and the control. Therefore, the two groups are here presented and 
statistically analyzed separately. It is anyway possible to draw common conclusions. The 
functional screening of the mutants can be summarized as follows: 	  
- 2 mutations (L445W and T193I) show a complete loss of function (the transport 
activity was not significantly different with respect to the control); 
 
- 4 mutations (P142L, G149R, C282Y and Q413R) showed a transport activity 
significantly reduced with respect to the wild type, but not completely annihilated 
(the transport activity was significantly higher with respect to the control); 
 
- the aminoacidic substitution R776C did not affect the transport of iodide with 
respect to wild type pendrin. 
 
 4.2 Subcellular localization of pendrin allelic variants 
 
Disclaimer: the subcellular localization studies were performed in our laboratories at the Paracelsus Medical 
University, Salzburg, in collaboration with the University of Campinas, Brazil. I have participated in part of the 
co-localization experiments. However, for sake of completeness, the whole co-localization results are 
presented in this section. 
 
The subcellular localization of the abovementioned pendrin allelic variants was 
determined in living HeLa cells by measuring the co-localization of the fluorescent signal 
emitted by the fusion protein pendrin-EYFP (PDS-EYFP) and two specific dyes, i.e. the 
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plasma membrane (CellMask Deep Red Plasma Membrane Stain) or the endoplasmic 
reticulum (ER-Tracker Red Glibenclamide BODIPY-TR) stains, respectively. 
In Figures 10 and 11, examples of fluorescence imaging and co-localization scatter 
plots from the experimental series are shown. In the scatter plots, the position of each 
pixel represents its fluorescence intensity in the emission channel of EYFP and in the 
emission channel of the marker of plasma membrane (Figure 10) or endoplasmic reticulum 
(Figure 11). Pixels situated along the diagonal of the plot show similar emission intensity in 
both channels and therefore represent co-localization of the two signals. In contrast, pixels 
distributed along the axes of the graph show higher emission intensity in one of the two 
channels and lower emission intensity in the other channel, therefore indicating mutual 
exclusion of the two signals. 
 
The co-localization was quantified by determining the Pearson’s correlation 
coefficient. As mentioned in the Methods section, the value of the Pearson’s coefficient 
can range between -1 and +1, where +1 represents complete co-localization, a value close 
to 0 is indicative of an absence of correlation and a value of -1 represents a complete 
mutual exclusion of the two signals within the region of interest. 
 
 
 
 
a)# b)#
Figure 10: a) Representative images of wild type pendrin (PDS-EYFP, green, top left) and the plasma 
membrane marker (magenta, top right). At the bottom left, the merge of the two images and at the bottom 
right the co-localization scatter plot are shown. White pixels in the merged image and pixels located along 
the diagonal of the scatter plot indicate co-localization between wild type pendrin and the plasma 
membrane. b) Representative mutated pendrin (L445W-EYFP, green, top left), plasma membrane 
(magenta, top right) and merge (bottom left) images and corresponding co-localization scatter plot 
(bottom right). The absence of white pixels in the merged image and pixels located along the axes of the 
scatter plot indicate exclusion between the mutated pendrin and the plasma membrane. Scale bar: 10 
µm. 
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The Pearson's correlation coefficient between PDS-EYFP and the plasma 
membrane or ER marker is calculated for every pendrin variant analyzed in the 
experimental series according to the formula reported in the methods. The calculated 
correlation values are compared to the wild type and a negative control (cells transfected 
with EYFP only). Being EYFP a water soluble protein, it is expected to show no significant 
co-localization with the plasma membrane. Accordingly, the respective Pearson’s 
correlation coefficient (black bar in Figure 12a) results significantly reduced with respect to 
wild type PDS-EYFP. The results are represented in Figure 12 and show the Pearson's 
correlation coefficients of co-localization with the plasma membrane (Figure 12a) and the 
endoplasmic reticulum (Figure 12b). Data were interpreted as follows: 
 
- pendrin variants with a Pearson’s correlation coefficient with the PM not significantly 
reduced with respect to the wild type but significantly higher with respect to the 
negative control have been considered to have PM targeting and are represented in 
white in panel a; 
- pendrin variants with a Pearson’s correlation coefficient with the PM significantly 
reduced with respect to the wild type have been considered to be excluded from the 
PM and are represented in grey in panel a; 
a)# b)#a)# b)#a)# b)#
Figure 11: a) Representative images of wild type pendrin (PDS-EYFP, green, top left) and the 
endoplasmic reticulum marker (red, top right). At the bottom left, the merge of the two images and at the 
bottom right the co-localization scatter plot are shown. The absence of yellow pixels in the merged 
image and pixels located along the axes of the scatter plot indicate an absence of co-localization 
between wild type pendrin and the endoplasmic reticulum. b) Representative mutated pendrin (Q413R-
EYFP, green, top left), endoplasmic reticulum marker (red, top right) and merge (bottom left) images and 
corresponding co-localization scatter plot (bottom right). Yellow pixels in the merged image and pixels 
located along the diagonal of the scatter plot indicate co-localization between the mutated pendrin and 
the endoplasmic reticulum. Scale bar: 10 µm. 	  
a)	  a)	   b)	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- pendrin variants with a Pearson’s correlation coefficient with the ER not significantly 
higher with respect to the wild type have been considered not to be retained in the 
ER and are represented in white in panel b; 
- pendrin variants with a Pearson’s correlation coefficient with the ER significantly 
higher with respect to the wild type have been considered to be retained in the ER 
and are represented in grey in panel b. 
 
To summarize, white bars in Figure 12 correspond to pendrin allelic variants with 
PM targeting and grey bars represents those variants that are instead significantly retained 
in the ER. The co-localization of the different pendrin variants with the plasma membrane 
is highly consistent with the co-localization with the endoplasmic reticulum, with those 
mutants showing a good co-localization with the PM being mostly excluded from the ER 
and viceversa. The only exception to this observation is the mutant G149R, showing a 
plasma membrane co-localization value comparable to the wild type in panel 12a but at 
the same time a significant co-localization with the endoplasmic reticulum as well, as 
shown in panel 12b. 
 
 
 
 
 
Figure 12: Pearson’s correlation coefficients of wild type pendrin-EYFP and different pendrin variants 
with the plasma membrane (a) and the endoplasmic reticulum (b). For the control, cells were transfected 
with a vector bearing the EYFP sequence alone. EYFP is homogeneously distributed in the cytosol, 
therefore does not show preferential localization neither with the PM, nor with the ER. ***p<0.001, 
**p<0.01 versus wild type (PDS WT-EYFP), one way ANOVA with Bonferroni’s post-test, n≥6. 
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 4.3 Evaluation of expression levels of pendrin allelic variants 
 
In association with different subcellular localization patterns, possible differences in 
the degree of expression of the different pendrin variants were also investigated and 
evaluated both at the whole cell, total membranes and plasma membrane level. The 
protein expression levels of wild type and mutant pendrin have been analyzed via two 
different experimental approaches: confocal imaging of pendrin-EYFP fusion proteins and 
western blotting on protein extracts from transfected cells. 
 
 4.3.1 Confocal imaging 
 
Two sets of experiments have been set up in order to quantify the amount of protein 
in the whole cell and plasma membrane region, with two different normalization methods.  
 
  4.3.1.1 Total pendrin expression 
 
To evaluate total pendrin expression, cells for imaging experiments were 
transfected with a plasmid bearing the cDNA coding for wild type or mutant pendrin with 
EYFP fused to the C-teminus (PDS-EYFP). Before imaging, the cells were fixed with 4% 
paraformaldehyde and stained with DAPI.	  	  
In the panels of figure 13, representative acquisition fields for the different pendrin 
variants analyzed are shown. For each mutant and the wild type, the acquisition in the 
emission channel of EYFP is shown beside the corresponding acquisition in the emission 
channel of DAPI. The intensity of the signal in both channels was expressed as averaged 
levels of grey. The mean signal intensity emitted by the fusion protein PDS-EYFP in the 
whole acquisition field was normalized for the cell density in the same field, represented by 
the signal emitted by the nuclear staining with DAPI (Figure 13).	   The results could be 
statistically analyzed in order to compare the expression levels of the different pendrin 
variants to the wild type (Figure 14). 	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Figure 13: confocal imaging of fixed HeLa cells transfected with the fusion protein pendrin-EYFP (wild 
type or mutated, yellow right panels). The normalization of the signal was performed according to the 
cell density in the field, given by the nuclear staining with DAPI (blue, left panels). Scale bar: 50 µM.	  	  
Figure 14: normalized total expression levels of pendrin-EYFP (wild type or mutated), expressed as ratio 
between pendrin-EYFP and DAPI emission intensities in the acquisition field. Pendrin variants that show 
a reduction of function according to the functional tests illustrated previously are marked in grey. The 
black bars identify those pendrin variants displaying a complete loss of function, while variants whose 
the function was not affected and the wild type are indicated by white bars. **p<0.01, *p<0.05 versus 
wild type, one way ANOVA with Bonferroni’s post-test, n=16.	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All the analyzed pendrin variants show a reduced overall expression, with the only 
exception of the variant R776C, whose expression levels are not statistically different from 
the wild type. The mutants with complete loss of function (T193I and L445W) show the 
lower expression levels. Surprisingly, also the mutant Q413R shows an extremely low 
expression level, comparable to the two loss of function mutations, even though it retains a 
residual transport activity.  
 
  4.3.1.2 Pendrin expression at the plasma membrane region 
 
For the analysis of pendrin abundance at the plasma membrane level, cells have 
been co-transfected with a plasmid bearing the cDNA coding for wild type or mutated 
pendrin, with EYFP fused at the C-terminus (PDS-EYFP), and a plasmid carrying the 
cDNA for ECFP alone, as an indicator of the transfection efficacy of the single cell (Figure 
15).  
 
As for the previous set of experiments, the intensity of the signal emitted in EYFP 
and ECFP channels was expressed as averaged levels of grey.  
 
In this case, the intensity of the signal emitted by PDS-EYFP in the plasma 
membrane region of a single cell has been normalized for the signal emitted by ECFP in 
the cytosol of the same cell (Figure 15). Furthermore, in order to efficiently identify the 
plasma membrane region, especially for those mutants previously shown to display a 
complete retention in the ER, cells have been treated with the same specific PM stain 
(CellMask Deep Red Plasma Membrane Stain) used in the co-localization experiments. 
 
The results were statistically analyzed in order to compare the expression levels of 
the different pendrin variants to the wild type (Figure 16).  
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Figure 15: confocal imaging of living HeLa cells co-transfected with the fusion protein pendrin-EYFP (wild 
type or mutated, green, middle panels) and ECFP (blue, left panels) as a marker of the transfection 
efficiency of the single cell. The signal emitted by pendrin-EYFP in the plasma membrane region was 
normalized for the emission of ECFP in the cytosol of the same cell. In order to efficiently identify the plasma 
membrane of cells, a fluorescent dye specific for the plasma membrane was used (magenta, right panels) 
Scale bar: 20 µM.	  	  
Figure 16: normalized plasma membrane expression levels of pendrin-EYFP (wild type or mutated) 
expressed as ratio between the signal emitted by pendrin-EYFP in the plasma membrane region and 
ECFP (expressed as averaged levels of grey) in individual cells. Pendrin variants that show a reduction 
of function according to the functional tests illustrated previously are marked in grey. Fully functional 
variants and the wild type are indicated by white bars. The black bars identify those pendrin variants 
displaying a complete loss of function. *p<0.05, **p<0.01 versus wild type, one way ANOVA with 
Bonferroni’s post-test, n=16.	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All the analyzed pendrin variants show a plasma membrane expression significantly 
reduced with respect to the wild type, with the only exception of R776C. A clear correlation 
between total and plasma membrane abundance can be observed for all the analyzed 
pendrin variants. Furthermore, expression levels of the different pendrin variants appear to 
be consistent with the level of transport activity determined previously via functional test 
(Figure 9). This important evidence will be better discussed in the next section. 
  
  4.3.2 Western Blot analysis 
 
The results of imaging experiments on the expression levels of pendrin were 
obtained with a fusion protein (PDS-EYFP) and refer to the total (intracellular plus plasma 
membrane) and plasma membrane pendrin abundance. Theoretically, the presence of a 
relatively big tag (the EYFP protein) fused to the C-terminus of pendrin may alter its folding 
and trafficking. In order to verify this last hypothesis, expression levels were also 
determined by western blot analysis following transfection of untagged wild type and 
mutated pendrin. 
 
Western blot analysis have been performed on protein extracts from HEK 293 
Phoenix cells transfected with wild type or mutant pendrin. In two separate sets of 
experiments, the expression of pendrin in total proteins and total membranes proteins 
fractions were analyzed.  
  
   4.3.2.1 Expression levels of pendrin in total cellular  
     proteins extracts 
 
HEK 293 Phoenix cells were transfected with pTARGET vectors bearing the cDNA 
of wild type or mutant pendrin. In this case the pTARGET vectors were mutated in order 
not to express the hexahistidine tag at the C-terminus of pendrin, since it was observed in 
an independent set of experiments that its presence prevents the binding of the anti-
pendrin antibody (data not shown). The negative control is a protein extract from mock 
transfected HEK 293 Phoenix cells. 
 
	  	   	  73	  
In Figure 17, a representative blot is reported, showing multiple bands 
corresponding to pendrin between 90 and 120 kDa and a single band corresponding to the 
housekeeping protein GAPDH between 35 and 40 kDa. Multiple bands around 90-120 kDa 
are to be ascribed to the multiple glycosylation states of the protein, as suggested by the 
findings of Azroyan et al. in 2010 [116] and confirmed by Cirello et al. in 2012 [117]. The 
bands corresponding to pendrin are clearly visible in the wild type and P142L lanes, 
whereas they are relatively faint in all the other lanes. However, it was possible to analyze 
the blot densitometrically (Figure 18). The complete lack of signal relative to pendrin in the 
lane corresponding to the mutant R776C is likely to be attributed to a conformational 
disruption of the epitope recognized by the anti-pendrin antibody due to the presence of 
the mutation in position 776. Accordingly, this antibody is known to target the C-terminus 
of pendrin [118]. It is to be noticed the higher intensity of the signal corresponding to the 
mutant P142L if compared to the wild type. This may be due to an accumulation of this 
particular protein form, circumventing the degradation process. 
 
 
 
The intensity of the bands corresponding to wild type and mutated pendrin was 
densitometrically determined and normalized to the intensity of the corresponding GAPDH 
band. Results show that the abundance of all pendrin variants in total protein extracts is 
strongly reduced compared to wild type, with the only exception of the mutant P142L that, 
unexpectedly, shows an expression level comparable to the wild type (Figure 18). 
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Figure 17: representative western blot from total protein extractions. The multiple bands between 90 and 
120 kDa correspond to the different glycosylation forms of pendrin. The single band right above 35 kDa 
corresponds to GAPDH (expected molecular weight: 36 kDa). Curiously, the variant P142L appears to 
show a stronger signal than the wild type. The lack of signal in the R776C lane may be due to the 
disruption of the epitope recognized by the antibody.	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   4.3.2.2 Expression levels of pendrin in total membranes  
     extracts 
 
For the analysis of pendrin expression in the total membranes fraction, a different 
protocol was followed. As for the previous set of experiments, HEK 293 Phoenix cells were 
transfected with pTARGET vectors coding for untagged wild type or mutant pendrin. The 
extraction of the total membranes fraction (including the plasma membrane as well as 
organelles membranes) was achieved with the Plasma Membrane extraction Kit. The 
whole pellet obtained was directly loaded on the gel after resuspension and denaturation 
in the Loading dye (see Methods). 
 
In Figure 19, a representative blot is displayed, showing multiple bands 
corresponding to pendrin between 90 and 120 kDa and the band corresponding to the 
housekeeping protein calreticulin right above 55 kDa (expected molecular weight: 62 kDa). 
Bands corresponding to mutated pendrin are now significantly more distinguishable 
compared to the blot represented in Figure 17. As in the previous western blots on total 
proteins extracts, no signal could be detected in the lane corresponding to R776C. 
Interestingly, the bands corresponding to P142L are now slightly less intense than the wild 
type, in contrast to what seen in the total proteins blot (Figure 17). 
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Figure 18: Densitometrical analysis of western blots on total protein extracts. Pendrin signal was 
normalized for the signal of the housekeeping protein GAPDH. The color of bars indicates the transport 
activity of the corresponding pendrin variant. n.s.: not statistically significant, *p<0.05, one way ANOVA 
with Dunnett’s post-test versus PDS WT, n=4. 	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The intensity of the bands corresponding to pendrin variants were densitometrically 
quantified and normalized according to the intensity of the corresponding calreticulin band 
(Figure 20). 
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Figure 19: representative western blot on total membranes proteins extractions. The bands between 90 
and 120 kDa correspond to the different glycosylation states of pendrin. The single band at ~60 kDa 
corresponds to calreticulin. The lack of signal in the R776C lane may be due to the disruption of the 
epitope recognized by the antibody.	  	  	  
Figure 20: Densitometrical analysis of western blots on total membranes proteins extracts. Pendrin 
signal was normalized for the signal of the housekeeping protein calreticulin. The color of bars indicates 
the transport activity of the corresponding pendrin variant. n.s.: not statistically significant, ***p<0.005, 
**p<0.01, *<0.05, one way ANOVA with Dunnett’s post-test versus PDS WT; #p<0.05, one way ANOVA 
with Dunnett’s post-test versus control, n=3. 	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Figure 20 includes the statistical analysis of western blot densitometry on total 
membranes proteins. All pendrin variants show membrane expression levels significantly 
reduced in relation to the wild type. Their expression level is statistically undistinguishable 
from the negative control, exception made for P142L.  
 
These results correlate very well with those of the imaging experiments described in 
the previous sections (Figures 14 and 16), thus supporting the evidence that expression 
levels of pendrin variants with function reduced or annihilated are significantly lower 
compared to wild type.  
 
  4.4 Rescue of pendrin activity 
 
All the functionally impaired pendrin variants analyzed in this work show reduced 
cellular expression levels with respect to the wild type and many of them are at least 
partially retained in the ER. Such evidence points to a role of the protein degradation 
machinery in the determination of the expression levels – and possibly, of the functional 
impairment – of pendrin mutants. 
 
The most common protein degradation pathway active in the cell involves the 
proteasome complex machinery. Proteins destined to degradation are driven to the 
proteasome by polyubiquitination signals. Within the proteasome complex, a series of 
proteolysis steps degrade the proteins to single aminoacids. Under this light, a possible 
rescuing approach of pendrin transport activity may start from the inhibition or modulation 
of such a degradation process.  
 
In order to test the effect of such a treatment, two sets of experiments were set up, 
in order to:  
 
(i) determine the effect of the inhibition of proteasomal degradation on the 
transport activity of pendrin mutants by means of the fluorometric 
functional test described in the previous sections; 
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(ii) determine the effect of the inhibition of proteasomal degradation on 
pendrin protein abundance by confocal imaging. As described in the 
previous sections, both the total and the plasma membrane pendrin 
abundance were analyzed. 
 
 4.4.1 Function of pendrin variants following inhibition of the ubiquitin 
   proteasome pathway 
 
HEK 293 Phoenix cells for the functional tests were co-transfected with the different 
pendrin variants and the fluorescent intracellular iodide sensor EYFP H148Q I152L. The 
cells were incubated for 6 hours in complete culture medium supplemented with the 
proteasome inhibitor MG132 (10 µM), or its vehicle (0.1% DMSO).  
 
The transport activity measured for the different pendrin variants in cells treated 
with MG132 was compared to the activity of the same variants in cells treated with the 
vehicle. This way it was possible to determine the efficacy of the proteasome inhibition on 
pendrin transport activity. In Figure 21, the results of the functional experiments are 
presented.  
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Figure 21: functional test on pendrin variants in cells treated with the proteasome inhibitor MG132 (10 
µM, dashed bars) or its vehicle (DMSO, open bars). The statistical difference between MG132 and 
vehicle-treated cells was tested for each pendrin variant analyzed. *p<0.05, **p<0.01, ***p<0.005, two-
tailed, unpaired Student’s t-test versus vehicle-treated cells, n=12.  	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From the functional tests, a significant effect of the treatment in 4 cases out of 9 (4 
out of 6 functionally impaired variants) emerges. Specifically, the transport activity of the 
functionally impaired pendrin variants P142L, T193I, Q413R and L445W significantly 
improved upon treatment of cells with MG132 with respect to the vehicle. MG132 
treatment was ineffective on cells transfected with the functionally impaired pendrin 
variants G149R and C282Y. In addition, the activity of wild type pendrin and the functional 
variant R776C were not modified. Importantly, the endogenous transport activity of control 
cells was not affected.  
 
 4.4.2 Expression levels of pendrin variants following inhibition of the 
   ubiquitin proteasome pathway 
 
 
In order to verify if the increased function of the above mentioned pendrin variants 
following inhibition of proteasomal degradation is the consequence of an increase in their 
expression levels, the protein abundance of pendrin variants was measured by 
fluorescence imaging upon treatment with MG132 or its vehicle (DMSO). 
 
Two sets of experiments were set up, as previously described. In the first set of 
experiments, the total pendrin abundance was evaluated, while in the second set of 
experiments, only pendrin abundance in the plasma membrane region was considered. 
 
   4.4.2.1 Total pendrin expression 
 
HeLa cells were transfected with the different variants of pendrin fused to EYFP 
(PDS-EYFP). 72 hours after transfection, the cells were incubated overnight at 37°C with 
complete media supplemented with 10 µM MG132 or its vehicle (0.1% DMSO). Before 
imaging, the cells were fixed with 4% paraformaldehyde and stained with DAPI. 
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The signal emitted by pendrin-EYFP in the whole acquisition field, expressed as 
averaged levels of grey, was normalized for the cell density in the same field according to 
the signal emitted by DAPI, also expressed as averaged levels of grey. The treatment with 
MG132 (Figure 22) induced a significant increase in the total expression levels of all 
pendrin variants, except for C282Y (in this case, only a not statistically significant tendency 
was observed). A strong effect was also recorded for wild type pendrin and for the 
Figure 22: fluorescence imaging of fixed HeLa cells transfected with pendrin variants and treated with 10 
µM MG132 or its vehicle. a) the effect of the proteasome inhibitor on the total expression levels of wild 
type and two representative pendrin variants (P142L, T193I) is shown in the picture. In the left ends 
panels, the acquisition in the emission channel of DAPI (blue) is shown. In the right ends panels, the 
emission of pendrin-EYFP (yellow) is shown. DAPI gives an indication of the cell density in the field, and 
was used to normalize the EYFP signal. Scale bar: 50 µm. b) Normalized expression levels determined 
for each pendrin variant and the control (EYFP). **p<0.01, ***p<0.005, two-tailed, unpaired Student’s t-
test versus vehicle-treated cells, n=12. 	  
	  a)	  
	  b)	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functional variant R776C. In all cases, upon treatment with MG132, the protein expression 
of the different hypofunctional variants reached at least the level of expression of wild type 
pendrin in vehicle-treated cells (dashed line in Figure 22). MG132 was ineffective in 
increasing the expression levels of EYFP protein in control cells. 
 
    4.4.2.2 Pendrin expression at the plasma membrane 
      region 
 
The same approach was used to determine pendrin expression in the plasma 
membrane region. In this series of experiments, as described in the previous sections, the 
signal emitted by pendrin-EYFP in regions of interest of the plasma membrane was 
normalized on the emission of ECFP in the cytosol of the same cell, as an indication of 
transfection efficacy of the single cell. 
 
As for the previous series of experiments, HeLa cells were transfected with the 
different mutant forms of pendrin fused to EYFP. 72 hours after transfection, the cells were 
incubated overnight at 37°C with 10 µM MG132 or its vehicle (DMSO). Right before 
imaging, living cells were stained with a specific PM dye (CellMask Deep Red Plasma 
Membrane Stain) as described in the methods. This staining was particularly necessary to 
identify the plasma membrane in cells transfected with those pendrin variants completely 
lacking a PM localization. 
 
In Figure 23a, a representative example of evaluation of plasma membrane 
abundance of a pendrin variant following MG132 treatment is shown. On the left end 
panels the emission of ECFP is presented, while in the right end panels the emission of 
pendrin P142L-EYFP is displayed. Top panels refer to cells treated with the vehicle, lower 
panels refer to cells treated with MG132. The emission of P142L in cells treated with the 
vehicle (top right) is to be compared to the emission of the same pendrin variant in cells 
treated with MG132 (bottom right). The increased expression in the plasma membrane 
region upon treatment with the proteasome inhibitor is clearly visible. The graph in Figure 
23b shows the expression levels of the different pendrin variants in the plasma membrane 
region normalized for the transfection efficacy of the single cell. For each variant, the 
plasma membrane expression levels with and without treatment with MG132 were 
compared. 
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A significant increase in plasma membrane expression upon treatment with MG132 
was observed for each hypofunctional variant analyzed, including C282Y. This last variant 
appeared to be irresponsive to MG132 in the previous set of experiments, when total 
pendrin expression was evaluated. No increase in the plasma membrane expression 
levels could be determined for wild type pendrin and for the functional variant R776C 
following MG132 treatment.  
Figure 23: a) representative picture of living HeLa cells for the quantification of pendrin expression in the 
PM region. The variant P142L is here represented. On the top right, the emission of pendrin P142L in 
cells treated with the vehicle is shown, to be compared with the emission of the same variant in cells 
treated with the proteasome inhibitor MG132 (10 µM, overnight, bottom right). In the left end panels, the 
signal emitted by ECFP in vehicle and MG132-treated cells is shown and was used to normalize the 
pendrin P142L-EYFP signal for the transfection efficacy of the single cell. Scale bar: 10 µm. b) 
normalized expression levels of pendrin-EYFP variants. **p<0.01, *p<0.05, two-tailed, unpaired 
Student’s t-test versus vehicle-treated cells, n=10.	  
	  a)	  
	  b)	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 4.5 Functional screening of pendrin ligands 
 
In the following sections the results of the functional screening of putative pendrin 
ligands are reported. The tested compounds are presented according to the rationales 
described in the introduction:  
 
• known inhibitors of chloride channels and transporters and inhibitors of 
transporters homolog to pendrin, such as Slc26a3 (DRA); 
 
• antihypertensive and diuretic agents; 
 
• small compounds predicted by a bioinformatic approach based on the 
abstraction of the primary aminoacidic sequence of pendrin, called meta-
analysis; 
 
• small compounds predicted by SHED alignment with established pendrin 
inhibitors. 
 
HEK 293 Phoenix cells were co-transfected with the pEYFP H148Q I152L and 
pTARGET PDS WT vectors or with the pEYFP H148Q I152L and pTARGET empty vectors 
as a negative control (empty). The substances or their vehicles were added to the 
extracellular high chloride and high iodide solutions. As described in detail in the methods 
section, an intracellular EYFP H148Q I152L-dependent fluorescence decrease indicates 
an influx of iodide in pendrin-transfected (PDS) or control (empty) cells. The decrease in 
intracellular fluorescence measured after iodide injection in the extracellular solution of 
cells over-expressing pendrin and treated with the test compound was compared to the 
decrease measured in vehicle-treated cells. At the same time, an eventual effect of the 
treatment on control cells was analyzed, in order to discriminate possible effects on 
endogenous transports, therefore not directly related to pendrin activity.  
For every reported substance, concentration and solvent are indicated. A brief 
description of the substance and its eventual use in the praxis are mentioned, as well as 
the rational driving the choice of the specific compound. The graphs show the results of the 
functional tests and the possible effect on pendrin-dependent or endogenous transport 
activity. The statistical analysis for all the presented results was performed by means of 
one-way ANOVA with Bonferroni’s post-test. 
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 4.5.1 Chloride channels and transporters blockers 
 
NPPB (5-nitro-2-(3-phenylpropylamino)benzoic acid)	   
 
 NPPB (Figure 24a) was included in the screening as it is a well known inhibitor of 
anion channels and was shown in previous experiments to inhibit pendrin-driven chloride 
uptake in HEK 293 Phoenix cells [1]. The final concentration of NPPB was 100 µM, the 
vehicle was 0.1% DMSO. 
 
 
  
 
 
A 32% inhibition (p<0.005) of iodide intake in pendrin-transfected cells (PDS) was 
determined upon treatment with NPPB with respect to the vehicle. No effect on control 
cells (empty) was measurable (Figure 24b). 	  
 
DIDS (4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid) 
 
DIDS (Figure 25a) was included in the screening as it is widely recognized as an 
anion exchanger and anion channels inhibitor [119]. The final concentration of DIDS was 
100 µM in 0.1% DMSO.   
a) b) 
Figure 24. a) Structural formula of NPPB. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM NPPB or its vehicle (0.1% DMSO). n=24, one-way ANOVA with Bonferroni’s 
post-test. ***p<0.005, n.s.: not significant. 
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with DIDS with respect to the vehicle-treated cells (Figure 25b).  	  
 
CFTR inhibitor-172 
 
 CFTR inhibitor-172 (Figure 26a) was included in the screening as it is a blocker of 
the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel [120]. 
The final concentration of CFTR inhibitor-172 was 1.6 µM [121] in 0.1% DMSO.   
 
 	  	  	  
 
a) 
b) 
a) 
b) 
Figure 25. a) Structural formula of DIDS. b) Functional test on HEK 293 Phoenix cells transfected with 
pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM DIDS or its vehicle (0.1% DMSO). n=48, one-way ANOVA with Bonferroni's 
post-test. ***p<0.005, n.s.: not significant. 
 
 
Figure 26. a) Structural formula of CFTR inhibitor-172. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 1.6 µM CFTR inhibitor-172 or its vehicle (0.1% DMSO). n=24, one-
way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with CFTR inhibitor-172 with respect to the vehicle-treated cells (Figure 
26b).  
 
 
DNDS (4',4'-dinitrostilbene-2,2'-disulfonic  acid) 
 
DNDS (Figure 27a) was included in the screening as a widely recognized anion 
channels and transporters inhibitor [122]. The final concentration of DNDS was 100 µM in 
isotonic solution.   
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with DNDS with respect to the vehicle-treated cells (Figure 27b).  
   
 
  4.5.2 Inhibitors of DRA and previously assessed inhibitors of  
  pendrin 
 
Niflumic acid 
 
 The anti-inflammatory drug niflumic acid (Figure 28a) was included in the screening 
as it was recognized to inhibit the pendrin analog DRA [123]. The final concentration of 
niflumic acid was 100 µM in 0.1% DMSO. 
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Figure 27. a) Structural formula of DNDS. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM DNDS or its vehicle (isotonic solution). n=12, one-way ANOVA with 
Bonferroni's post-test. ***p<0.005, n.s.: not significant. 
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A 28% inhibition (p<0.005) of iodide intake in pendrin transfected cells was 
determined upon treatment with niflumic acid with respect to the vehicle-treated cells. No 
effect on control cells was measurable (Figure 28b). In some experiments though, an 
intracellular acidification was observed (see discussion).  
 
 
Tenidap 
 
 The anti inflammatory drug tenidap (Figure 29a) was included in the screening as 
inhibitor of Cl-/HCO3- exchange [124] and inhibitor of pendrin analog DRA [107]. The final 
concentration of tenidap was 100 µM in 0.1% DMSO.   
 
 
a) b) 
a) 
b) 
Figure 28. a) Structural formula of niflumic acid. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM niflumic acid or its vehicle (0.1% DMSO). n=12, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, *p<0.05, n.s.: not significant.  
 
Figure 29. a) Structural formula of tenidap. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM tenidap or its vehicle (0.1% DMSO). n=18, one-way ANOVA with Bonferroni's 
post-test. ***p<0.005, **p<0.01, n.s.: not significant.  
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An 85% inhibition (p<0.01) of iodide intake in pendrin transfected cells was 
determined upon treatment with tenidap with respect to the vehicle-treated cells. No effect 
on control cells was measurable (Figure 29b).  
 
 
Glybenclamide 
 
 Glybenclamide (Figure 30a) was included in the screening as inhibitor of the 
pendrin analog, DRA [107]. The final concentration of glybenclamide was 100 µM in 0.1% 
DMSO.   
 
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected cells was determined upon 
treatment with glybenclamide with respect to the vehicle-treated cells (Figure 30b). A slight 
effect on control cells was observed, possibly due to an effect of glybenclamide on 
endogenous transports.  
 
 
Probenecid 
 
 Probenecid (Figure 31a) is an uricosuric drug used for treatment of gout and 
hyperuricemia. An inhibitory effect on pendrin has been shown by Scott et al. in 1999 [99]. 
The final concentration of probenecid was 100 µM in 0.1% chloroform.   
 
a) b) 
Figure 30. a) Structural formula of glybenclamide. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM glybenclamide or its vehicle (0.1% DMSO). n=24, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, *p<0.05, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with probenecid with respect to the vehicle-treated cells (Figure 31b).  
 
   
  4.5.3 Diuretics and antihypertensive agents 
 
Eplerenone 
 
 Eplerenone (Figure 32a) is an aldosterone antagonist exerting a diuretic effect. The 
final concentration of eplerenone was 10 µM in 0.1% DMSO, due to its poor solubility.   
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Figure 31. a) Structural formula of probenecid. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM probenecid or its vehicle (0.1% chloroform). n=30, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant. 
 
Figure 32. a) Structural formula of eplerenone. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 10 µM eplerenone or its vehicle (0.1% DMSO). n=36, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with eplerenone with respect to the vehicle-treated cells (Figure 32b).  
 
 
Acetazolamide 
 
 Acetazolamide (Figure 33a) is a carbonic anhydrase inhibitor with a diuretic effect. 
The final concentration of acetazolamide was 100 µM in 0.1% DMSO.   
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with acetazolamide with respect to the vehicle-treated cells (Figure 33b).  
 
 
Bumetanide 
 
 Bumetanide (Figure 34a) is a blocker of chloride reabsorption in the ascending loop 
of Henle [125]. The final concentration of bumetanide was 100 µM in 0.1% DMSO. 
 
 
 
a) 
b) 
a) 
b) 
Figure 33. a) Structural formula of acetazolamide. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM acetazolamide or its vehicle (0.1% DMSO). n=30, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
Figure 34. a) Structural formula of bumetanide. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM bumetanide or its vehicle (0.1% DMSO). n=24, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
	  	   	  90	  
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with bumetanide with respect to the vehicle-treated cells (Figure 34b).  
 
 
Furosemide 
 
 Furosemide (Figure 35a) is a blocker of the Na+-K+-2Cl- cotransporter in the 
ascending loop of Henle. Its final concentration was 100 µM in 0.1% DMSO.  
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with furosemide with respect to the vehicle-treated cells (Figure 35b).  
 
 
Amiloride 
 
 Amiloride (Figure 36a) is a blocker of the epithelial Na+ channel (ENaC) in the distal 
nephron. The final concentration of amiloride was 100 µM in 0.1% DMSO.   
 
 
 
 
 
a) b) 
a) 
b) 
Figure 36. a) Structural formula of amiloride. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM amiloride or its vehicle (0.1% DMSO). n=12, one-way ANOVA with Bonferroni's 
post-test. ***p<0.005, n.s.: not significant.  
 
Figure 35. a) Structural formula of furosemide. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty  vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM furosemide or its vehicle (0.1% DMSO). n=24, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
	  	   	  91	  
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with amiloride with respect to the vehicle-treated cells (Figure 36b).  
 
 
Hydrochlorothiazide 
 
 Hydrochlorothiazide (HCTZ, Figure 37a) is a blocker of the Na+-Cl- cotransporter 
(NCC). The final concentration of hydrochlorothiazide was 100 µM in 0.1% DMSO. 
  
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with hydrochlorothiazide with respect to the vehicle-treated cells (Figure 
37b).  
 
The following  common diuretic and anti-hypertensive agents have also been tested 
for their potential effect on pendrin activity: 100 µM Methazolamide, 100 µM Triamterene, 
100 µM Torsemide, 100 µM Hydroflumethiazide, 100 µM Indapamide, 100 µM 
Chlorothiazide, 100 µM Spironolactone. No inhibition of iodide intake in pendrin 
transfected or control cells was determined upon  treatment with any of the mentioned 
substances. 
 
   
 
a) b) 
Figure 37. a) Structural formula of hydrochlorothiazide. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM hydrochlorothiazide or its vehicle (0.1% DMSO). n=12, one-
way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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  4.5.4 Meta-analysis  
 
Meta analysis prediction and further SHED alignments were performed by Prof. R. 
Konrat at the institute of Biochemistry & Biophysics, Structural & Computational Biology, 
University of Vienna (Austria) and the results were delivered to us in form of a list of 
reference numbers corresponding to entries in the drugbank reference database 
(www.drugbank.ca).  
 
A selection of the compounds was then subjected to the functional test and results 
are presented in the following. 
 
 
Cholesterol 
 
Cholesterol (Figure 38a) was used to a final concentration of 100 µM in 0.1% 
chloroform.   
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with cholesterol with respect to the vehicle (Figure 38b).  
 
 
 
 
a) 
b) 
Figure 38. a) Structural formula of cholesterol. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM cholesterol or its vehicle (0.1% chloroform). n=6, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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Iloprost (Ilomedin® - Bayer) 
 
Iloprost (Figure 39a) is the active ingredient of Ilomedin®, a drug used to treat 
pulmonary arterial hypertension. Two different concentrations of Iloprost were tested: the 
therapeutic concentration (130 nM) and the 66 µM concentrated formulation.  
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected cells was determined upon 
treatment with Iloprost with respect to the vehicle-treated cells (Figure 39b-c). An effect on 
control cells may hint to disturbance of endogenous transports. 
 
 
Vasopressin 
 
The concentration of Vasopressin (Figure 40a) used was 1 µM in isotonic solution. 
The concentration was chosen to mimic the physiological circulating hormone levels.   
 
 
 
 
 
 
a) b) c) 
a) b) 
Figure 39. a) Structural formula of Iloprost. Functional test on HEK 293 Phoenix cells transfected with 
pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 13 nM (b) or 66 µM (c) Iloprost or its vehicle (isotonic solution). n=12, one-way ANOVA 
with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
Figure 40. a) Structural formula of vasopressin. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM vasopressin or its vehicle (high chloride solution). n=6, one-
way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with vasopressin with respect to the vehicle-treated cells (Figure 40b).  	  	  
Vitamin D4 (Dihydrotachysterol) 
 
The concentration of vitamin D4 (Figure 41a) tested was 100 µM in 0.1% DMSO.  
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with vitamin D4 with respect to the vehicle-treated cells (Figure 41b).  	  	  
Vitamin E (α-Tocopherol) 
 
The concentration of vitamin E (Figure 42a) used was 100 µM in 0.1% chloroform.  
 
 
 
 
 
a) 
b) 
a) b) 
Figure 41. a) Structural formula of vitamin D4. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM Vitamin D4 or its vehicle (0.1% DMSO). n=24, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant. 
 
Figure 42. a) Structural formula of vitamin E. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM Vitamin E or its vehicle (0.1% DMSO). n=24, one-way ANOVA with 
Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with vitamin E with respect to the vehicle-treated cells (figure 42b).  
 
 
(-)Nicotine  
 
Nicotine (Figure 43a) was used to a final concentration of 100 µM in isotonic high 
chloride solution.  
 
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with (-)Nicotine with respect to the vehicle-treated cells (Figure 43b) 
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Figure 43. a) Structural formula of (-)Nicotine. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM (-)Nicotine or its vehicle (high chloride solution). n=6, one-
way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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 4.5.5 SHED alignment	   
 
The identification of active compounds from the preliminary screenings allows for 
further refinement of the search of candidate ligands for pendrin. An alignment according 
to the SHED profile has been therefore performed for the two most promising compounds 
identified so far: the anti-inflammatory drugs tenidap and niflumic acid. 
 
In the following section the compounds resulting from such alignment are 
presented, first those derived from tenidap alignment and then those predicted from 
niflumic acid alignment. 
 
 
N-(2-chlorophenyl)-2-(2,4-dibromophenoxy)acetamide  
 
A possible effect of N-(2-chlorophenyl)-2-(2,4-dibromophenoxy)acetamide (Figure 
44a) was predicted by the SHED alignment of tenidap. N-(2-chlorophenyl)-2-(2,4-
dibromophenoxy)acetamide was used to a final concentration of 100 µM in 0.1% DMSO 
solution.  
 
 
 
 
 
 
 
 
A slight, but significant (14%, p<0.005), effect on iodide intake in pendrin 
transfected cells upon treatment with N-(2-chlorophenyl)-2-(2,4-
dibromophenoxy)acetamide was measured with respect to the vehicle-treated cells. An 
effect of the treatment can also be observed on control cells (Figure 44b). 
PD
S +
 ve
hic
le
em
pty
 + 
ve
hic
le
PD
S +
 tr
ea
tm
en
t
em
pty
 + 
tre
atm
en
t
-100
-80
-60
-40
-20
0
***
***
***
***
n=6
flu
or
es
ce
nc
e 
%
 v
ar
ia
tio
na) b) 
Figure 44. a) Structural formula of N-(2-chlorophenyl)-2-(2,4-dibromophenoxy)acetamide. b) 
Functional test on HEK 293 Phoenix cells transfected with pendrin or with an empty vector as a 
control. A fluorescence decrease (negative fluorescence % variation) indicates an influx of iodide in 
pendrin-transfected (PDS) or control cells (empty) following treatment with 100 µM N-(2-chlorophenyl)-
2-(2,4-dibromophenoxy)acetamide (treatment) or its vehicle (0.1% DMSO). n=6, one-way ANOVA with 
Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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2-{[(2,3-dichlorophenyl)methyl]amino}-1-phenylethanol 
 
A possible effect of 2-{[(2,3-dichlorophenyl)methyl]amino}-1-phenylethanol (Figure 
45a) was predicted by the SHED alignment of tenidap. The compound was used to a final 
concentration of 100 µM in 0.1% DMSO solution.  
 
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with 2-{[(2,3-dichlorophenyl)methyl]amino}-1-phenylethanol with respect to 
the vehicle-treated cells (Figure 45b). 
 
 
Naloxone 
 
A possible effect of the opioid antagonist naloxone (Figure 46a) was predicted by 
the SHED alignment of tenidap. Naloxone was used to a final concentration of 100 µM in 
0.1% DMSO solution.  
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Figure 45. a) Structural formula of 2-{[(2,3-dichlorophenyl)methyl]amino}-1-phenylethanol. b) 
Functional test on HEK 293 Phoenix cells transfected with pendrin or with an empty vector as a 
control. A fluorescence decrease (negative fluorescence % variation) indicates an influx of iodide in 
pendrin-transfected (PDS) or control cells (empty) following treatment with 100 µM 2-{[(2,3-
dichlorophenyl)methyl]amino}-1-phenylethanol (treatment) or its vehicle (0.1% DMSO). n=12, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
Figure 46. a) Structural formula of naloxone. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM naloxone or its vehicle (0.1% DMSO). n=12, one-way ANOVA with Bonferroni's 
post-test. ***p<0.005, n.s.: not significant. 
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with naloxone with respect to the vehicle-treated cells (Figure 46b). 
 
 
Tolcapone 
 
A possible effect of tolcapone (Figure 47a) was predicted by the SHED alignment of 
tenidap. Tolcapone was used to a final concentration of 100 µM in 0.1% DMSO solution.  
 
 
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with tolcapone with respect to the vehicle (Figure 47b). 
 
 
Topiramate 
 
A possible effect of the anticonvulsant and antiepileptic drug topiramate (Figure 
48a) was predicted by the SHED alignment of tenidap. Topiramate was used to a final 
concentration of 100 µM in 0.1% DMSO solution.  
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Figure 47. a) Structural formula of tolcapone. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM tolcapone or its vehicle (0.1%DMSO). n=24, one-way ANOVA with Bonferroni's 
post-test. ***p<0.005, n.s.: not significant.  
 
Figure 48. a) Structural formula of topiramate. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM topiramate or its vehicle (0.1% DMSO). n=12, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with topiramate with respect to the vehicle (Figure 48b). 
 
Colchicine 
 
A possible effect of colchicine (Figure 49a) was predicted by the SHED alignment of 
tenidap. Colchicine was used to a final concentration of 100 µM in 0.1% ethanol solution.  
 
  
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with colchicine with respect to the vehicle (Figure 49b). 
 
 
Scopolamine 
 
A possible effect of scopolamine (Figure 50a) was predicted by SHED alignment of 
tenidap. Scopolamine was used to a final concentration of 100 µM in isotonic high chloride 
solution.  
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Figure 49. a) Structural formula of colchicine. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM colchicine or its vehicle (0.1% ethanol). n=18, one-way ANOVA with 
Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
Figure 50. a) Structural formula of scopolamine. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM scopolamine or its vehicle (high chloride solution). n=12, one-
way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with scopolamine with respect to the vehicle (Figure 50b). 
 
 
Levamisol ((S)-(−)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride) 
 
A possible effect of the anthelmintic and immunomodulator drug levamisol (Figure 
51a) was predicted by the SHED alignment of niflumic acid. Levamisol was used to a final 
concentration of 100 µM in isotonic high chloride solution.  
 
  
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with levamisol with respect to the vehicle (Figure 51b). 
 
 
6-phenylamino nicotinic acid 
 
A possible effect of 6-phenylamino nicotinic acid (Figure 52a) was predicted by the 
SHED alignment of niflumic acid. 6-phenylamino nicotinic acid was used to a final 
concentration of 100 µM in 0.1% DMSO solution.  
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Figure 51. a) Structural formula of levamisol. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM levamisol or its vehicle (high chloride solution). n=12, one-way ANOVA with 
Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
 
Figure 52. a) Structural formula of 6-phenylamino nicotinic acid. b) Functional test on HEK 293 
Phoenix cells transfected with pendrin or with an empty vector as a control. A fluorescence decrease 
(negative fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control 
cells (empty) following treatment with 100 µM 6-phenylamino nicotinic acid or its vehicle (0.1% 
DMSO). n=18, one-way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with 6-phenylamino nicotinic acid with respect to the vehicle (Figure 52b). 
 
 
Levallorphan 
 
A possible effect of levallorphan (Figure 53a) was predicted by the SHED alignment 
of niflumic acid. Levallorphan was used to a final concentration of 100 µM in isotonic high 
chloride solution.  
 
   
 
 
 
No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with levallorphan with respect to the vehicle (Figure 53b). 
 
 
Ticlopidine 
 
A possible effect of the antiplatelet drug ticlopidine (Figure 54a) was predicted by 
the SHED alignment of niflumic acid. Ticlopidine was used to a final concentration of 100 
µM in isotonic high chloride solution.  
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Figure 53. a) Structural formula of levallorphan. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM levallorphan or its vehicle (high chloride solution). n=12, one-
way ANOVA with Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
 
Figure 54. a) Structural formula of ticlopidine. b) Functional test on HEK 293 Phoenix cells transfected 
with pendrin or with an empty vector as a control. A fluorescence decrease (negative fluorescence % 
variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells (empty) following 
treatment with 100 µM ticlopidine or its vehicle (high chloride solution). n=12, one-way ANOVA with 
Bonferroni's post-test. ***p<0.005, n.s.: not significant.  
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No inhibition of iodide intake in pendrin transfected or control cells was determined 
upon treatment with ticlopidine with respect to the vehicle (Figure 54b). 
 
 
Flufenamic acid 
 
A possible effect of flufenamic acid (Figure 55a) was predicted by the SHED 
alignment of niflumic acid. Flufenamic acid was used to a final concentration of 100 µM in 
a 0.1% DMSO solution.  
 
   
 
 
 
 
A 15% inhibition (p<0.01) of iodide intake in pendrin transfected cells was 
determined upon treatment with flufenamic acid with respect to the vehicle-treated cells 
(Figure 55b). As seen with the close analog of flufenamic acid, niflumic acid, an 
acidification of the intracellular pH was measured in some experiments (see discussion). 
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Figure 55. a) Structural formula of flufenamic acid. b) Functional test on HEK 293 Phoenix cells 
transfected with pendrin or with an empty vector as a control. A fluorescence decrease (negative 
fluorescence % variation) indicates an influx of iodide in pendrin-transfected (PDS) or control cells 
(empty) following treatment with 100 µM flufenamic acid or its vehicle (0.1% DMSO). n=24, one-way 
ANOVA with Bonferroni's post-test. ***p<0.005, **p<0.01, n.s.: not significant.  
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All the above reported results are summarize in table 6. The tested compounds are 
again classified according to the rationale described above. In the last section of the table, 
the compounds derived from the SHED profile alignment of niflumic acid and tenidap are 
listed. 
 
 
Compound Concentration Vehicle Effect 
1. Chloride channels and transporters blockers 
NPPB 100 µM DMSO 0.1% 32% inhib. 
DIDS 100 µM DMSO 0.1% No 
CFTR-inhibitor 172 1.6 µM DMSO 0.1% No 
DNDS 100 µM Isotonic solution No 
2. Previously identified inhibitors of SLC26A3 (DRA) or SLC26A4 (pendrin) 
Niflumic acid 100 µM DMSO 0.1% 28% inhib. (1) 
Tenidap 100 µM DMSO 0.1% 85% inhib. 
Glybenclamide 100 µM DMSO 0.1% No 
Probenecid 100 µM Chloroform 0.1% No 
Hydroxycinnamate 100 µM DMSO 0.1% No 
 3. Diuretics and antihypertensive agents 
Eplerenone 10 µM DMSO 0.1% No 
Acetazolamide 100 µM DMSO 0.1% No 
Bumetanide 100 µM DMSO 0.1% No 
Furosemide 100 µM DMSO 0.1% No 
Amiloride 100 µM DMSO 0.1% No 
Hydrochlorothiazide 100 µM DMSO 0.1% No 
Methazolamide 100 µM Isotonic solution No 
Triamterene 100 µM PEG400 5% No 
Torsemide 100 µM EtOH 0.1% No 
Hydroflumethiazide 100 µM DMSO 0.1% No 
Indapamide 100 µM EtOH 0.1% No 
Chlorothiazide 100 µM DMSO 0.1% No 
Spironolactone 100 µM EtOH 0.1% No 
4a. Meta-analysis 
Cholesterol 100 µM Chloroform 0.1% No 
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Iloprost® 
66 µM -- No* 
130 nM Isotonic solution No* 
Vasopressin 1 µM Isotonic solution No 
Vitamin D 100 µM DMSO 0.1% No 
Vitamin E 100 µM Chloroform 0.3% No 
Nicotine 100 µM Isotonic solution No 
4b. Niflumic acid and Tenidap SHED alignment 
N-(2-chlorophenyl)-2-(2,4-
dibromophenoxy)acetamide  100 µM DMSO 0.1% 14% inhib.* 
2-{[(2,3-dichlorophenyl)methyl] 
amino}-1-phenylethanol 100 µM DMSO 0.1% No 
Scopolamine 100 µM Isotonic solution No	  
Colchicine 100 µM EtOH 0.1% No	  
Topiramate 100 µM DMSO 0.1% No	  
Tolcapone 100 µM DMSO 0.1% No	  
Naloxone 100 µM DMSO 0.05% No	  
Levamisole 100 µM Isotonic solution No	  
6-phenylamino nicotinic acid 100 µM DMSO 0.1% No	  
Levallorphan 100 µM Isotonic solution No	  
Ticlopidine 100 µM Isotonic solution No	  
Flufenamic acid 100 µM DMSO 0.1% 15% inhib. (1)	  
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Summary of the functional screening of pendrin ligands. *: effect on control cells, probably 
due to an effect of the treatment on endogenous transports. (1) acidification of intracellular pH was 
measured. Acidic pH may influence the measurement by quenching the fluorescence of EYFP. 	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5. Discussion 
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 5.1 Functional and molecular characterization of pendrin   
  variants 
 
The genetic screening of a cohort of 58 deaf patients performed by our 
collaborators at the hospital of Campinas, Sao Paolo, Brazil, identified 14 patients with 
mutations in the pendrin coding region. The patients were all diagnosed with severe to 
profound deafness with or without EVA. 9 out of 14 patients display a heterozygous 
phenotype with one wild type and one mutated pendrin allele, two of which are double 
heterozygous with a monoallelic pendrin mutation and the monoallelic 35delG mutation in 
the GJB6 gene. Due to the high phenotypic variability observed among individuals with 
pendrin mutations and the high incidence of benign polymorphisms [74], it is not possible 
to establish if a specific pendrin variant is the genetic determinant of deafness in a given 
patient without a functional characterization. Only 5 of the 14 allelic variants identified in 
the screening had already been characterized previously (R409H, T410M, V138F, V609G, 
R776C), one variant (R776C) showing discordant results in the literature [63, 72-74]. For 
all the other variants no functional characterization is available in the literature. 
 
In the present study, the functional and molecular characterization of the 
uncharacterized pendrin variants identified in the abovementioned genetic screening have 
been performed, in order to define a genetic diagnosis for the observed deafness 
phenotype of the patients. The functional characterization, performed by means of the 
fluorometric assay described in the methods, delivers important information regarding the 
possible etiology of deafness in the patients examined (Table 7, boldface). The definition 
of a correct genetic diagnosis of the disease is important in order to exclude other genetic 
or environmental causes of deafness for which a specific treatment may exist. 
Furthermore, with a defined genetic diagnosis it is possible to provide the patient and the 
family with the more efficient counseling, both regarding an eventual progression of the 
disease with involvement of other organs (such as the thyroid) and the possibility of 
genetic transmission to the offsprings [6]. 
 
For what concerns this specific study, we can conclude that the functional 
impairment of pendrin is most likely the factor determining deafness in at least 5 patients 
out of 14 of this cohort (21AA, 06AA, 23AA, 22AA and 02AA, Table 7) as discussed in the 
following.  
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Patient 21AA has been diagnosed deaf with an enlarged vestibular aqueduct. The 
sequencing of pendrin coding region revealed the deletion 297T on one allele, leading to a 
truncated form of the protein. The variant P142L is encoded by the other allele. By means 
of our functional test, the variant P142L was defined as a mutation with reduction of 
function. It has previously been assessed that all pendrin truncations identified so far are 
non-functional [5], we can therefore conclude that the diagnosed deafness phenotype in 
patient 21AA is due to pendrin dysfunction, with no need of further investigations. The 
same conclusion can be drawn for patient 06AA, also diagnosed deaf with EVA. In this 
patient, the Q413R variant is encoded by one allele and the V138F variant by the second 
allele. The latter was previously characterized as a complete loss of function mutation [40], 
while the former has been characterized as a hypofunctional mutation in the present study. 
Patient 23AA bears a mutation affecting the splicing of pendrin messenger RNA on one 
allele, leading to a premature truncation of the protein. The second pendrin allele encodes 
for the L445W variant. L445W has been characterized in the present study as a complete 
loss of function mutation. Therefore, also in this case it is possible to identify pendrin 
dysfunction as the determinant factor for the development of deafness. Furthermore, this 
is the only patient in the cohort for which overt goiter was identified. Deafness associated 
to pendrin mutations and goiter are clear hallmarks of Pendred syndrome. The situation of 
patients 22AA and 02AA appear clear as well, as they both carry non-functional or 
hypofunctional pendrin variants characterized in previous studies (R409H in homozygosity 
and T410M and the splicing site mutation IVS15+5G>A, respectively [40,44]). Different is 
the case of patient C26. This patient was diagnosed deaf but with no abnormally enlarged 
vestibular aqueduct. From the genetic screening, a 35delG mutation on the connexin-26 
coding gene, GJB6, was identified, in association with a mutated form of pendrin carrying 
the aminoacidic substitution C282Y. 35delG mutation of the connexin-26 has been 
assessed in a number of studies as the most common genetic cause of deafness [60]. The 
pendrin variant C282Y has been characterized as hypofunctional mutation in the present 
study. We can therefore hypothesize that a monoallelic connexin-26 mutation combined 
with a monoallelic pendrin mutation (i.e. a condition of double heterozygosity) may be the 
genetic determinant of deafness for this patient. Patients 16AA and 18AA both present a 
mutant form of the transporter in heterozygosity with the wild type. The former carries the 
G149R variant, characterized here as reduction of function mutation, the latter displays the 
T193I variant, characterized as well in this study as a complete loss of function mutation. 
In both cases it is possible to hypothesize that either these patients are examples of 
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nonsyndromic-EVA due to monoallelic pendrin mutations [53, 67] or that further genetic or 
environmental factors may contribute to the development of the symptoms. The first 
candidates to be considered for further genetic investigations are the transcription factor 
FOXI1 and the potassium channel KCNJ10 [88, 89], both known to be involved in 
deafness with EVA. In this study, both genes have been sequenced and were found wild 
type, therefore excluding their role in the observed deafness phenotype. Further genetic 
aspects to be considered are possible mutations in the promoter and in the 3' untranslated 
region of pendrin gene, possibly affecting the transcription of the gene and expression 
levels of mRNA. In the case of patient 15AA, the R776C variant is encoded by one pendrin 
allele. From the functional tests presented in this study, such aminoacidic substitution 
does not affect the transport activity of pendrin and the corresponding pendrin variant has 
to be considered as a benign polymorphism. The presence of this particular allelic variant 
in association with the wild type allele excludes a role of pendrin in the development of 
deafness in this specific case. 
 
A particularly controversial situations is the one regarding the variant V609G in 
heterozygosis with the wild type allele. This aminoacidic substitution has been previously 
assessed as a mutation leading to a reduction of function [68]. In the present study it has 
been detected in heterozygosis with the wild type both in the group of patients with EVA 
(patient L1AA) and in the group with no EVA (patients C01, C04 and C09). In the case of 
patient L1AA, this pendrin mutation is associated with a monoallelic del35G mutation of 
the connexin-26 coding gene (GJB6), therefore we may hypothesize that this genetic 
configuration (double heterozygosis with the wild type) may be the actual determinant for 
the observed EVA and deafness. In this view, the V609G mutation alone would not be 
sufficient to determine EVA, and for patients C01, C04 and C09 other genetic or 
environmental causes of deafness should be taken into account. On the other hand, a 
similar genetic situation is present in the patient C26, where a reduction of function 
pendrin mutation (C282Y) is associated with the same monoallelic del35G mutation on 
GJB6. In this case no EVA could be observed. C282Y has been shown in the present 
study to be localized at the plasma membrane, therefore its molecular defect may be mild 
enough to allow for a sufficient transport activity and prevent EVA and deafness in patient 
C26, even in the presence of a defective connexin-26. 
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Patient 
(n=58) 
Aminoacidic 
substitution 
Patient Genotype 
(coding region) Goiter Function Localization 
Pendrin 
related 
defaness? 
 
 Patients deaf with EVA (n=26) 
 
21AA P142L P142L/del 297T No reduced PM YES 
16AA G149R G149R/WT No reduced PM/ER ? 
18AA T193I T193I/WT No lost ER ? 
22AA R409H R409H/R409H No lost/red. Partially PM YES 
02AA T410M T410M/IVS15+5G>A No lost ER YES 
06AA Q413R Q413R/V138F No reduced ER YES 
23AA L445W L445W/IVS8+1G>A Yes lost ER YES 
L1AA V609G V609G/WT * No reduced ? ? 
15AA R776C R776C/WT No unaffected PM NO 
 
 Patients deaf without EVA (n=32) 
 
C15 V138F V138F/WT No lost ER ? 
C26 C282Y C282Y/WT * No reduced PM ? 
C01 V609G V609G/WT No reduced ? ?	  
C04 V609G V609G/WT No reduced ? ?	  
C09 V609G V609G/WT No reduced ? ?	  
 
 
 
Further investigations were conducted in the present study, in order to determine 
the molecular defect leading to the measured functional impairment. The knowledge of the 
fate the different mutant forms undergo is the key for a possible pharmacological rescue of 
the transport activity. For this purpose, two molecular aspects have been investigated: the 
subcellular localization of the different variants and their abundance in the cell and in the 
plasma membrane region. 
 
Concerning the subcellular localization of the characterized mutants, the results 
obtained from the co-localization experiments with the plasma membrane or with the 
endoplasmic reticulum show a high variability in the distribution. The observed sub-cellular 
distributions range from a complete retention in the ER to a trafficking to the PM 
comparable to the wild type.  
Table 7: updated from Table 1. The results obtained in the present study are reported in boldface. 
*: mono allelic mutation (35delG) in the connexin-26 gene, GJB2, was also found. 
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The determined subcellular localization correlates quite well with the measured 
functional state of the different variants. The mutants showing the most severe functional 
impairment (the loss of function mutants T193I and L445W, Figure 9) are retained in the 
ER and completely excluded from the PM (Figure 12). Accordingly, hypofunctional forms 
of the transporters maintaining significant transport activity (P142L, G149R, C282Y, Figure 
9) are still able to reach the plasma membrane, at least partially (Figure 12). Such an 
observation may be an indication that specific aminoacidic substitutions, such as P412L 
and C282Y do not impair the folding and/or trafficking of the protein but may instead lie in 
a domain important for the binding of transported ions or regulatory factors, therefore 
directly affecting the transport activity. The mutant G149R is the only one showing a mixed 
subcellular localization profile, displaying significant co-localization with the plasma 
membrane but also with the endoplasmic reticulum (Figure 12). In this case, the folding 
defect may not be as severe as for other mutants and may still allow for a partial trafficking 
to the plasma membrane. The residual function measured in the functional tests for this 
particular mutant may be due to this partial trafficking to the plasma membrane. Other 
mutants (T193I, Q413R and L445W, Figure 12) are clearly retained in the endoplasmic 
reticulum. These specific mutations may therefore reside in a domain of the protein critical 
for its correct processing and folding. The fully functional variant R776C results mainly 
localized at the plasma membrane, with a behavior indistinguishable from the wild type 
(Figure 12), therefore confirming its nature of benign polymorphism. 
 
In summary, it seems that a severe loss of function correlates with a complete 
retention in the ER, while a residual transport activity is associated to a good trafficking to 
the plasma membrane. The mutant Q413R appears to represent an exception to this rule. 
This particular mutant showed a very strong co-localization with the endoplasmic reticulum 
and a complete exclusion from the plasma membrane, but in the functional tests it showed 
a reduction of function, with some residual transport activity. It is still possible that a small 
amount of this mutant, even if generally misfolded, is still capable of reaching the plasma 
membrane, accounting for the residual activity recorded. Considering that only an 
undetectable amount of protein can reach the plasma membrane, the fact that its activity 
was not completely abolished is surprising, and it may even be possible to hypothesize 
that the intrinsic transport ability of this particular mutant could be higher than the wild type 
itself, compensating for the impaired trafficking. 
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The fact that some pendrin mutants show a retention in the ER can point to the 
failure in the processing and folding of the protein. Misfolded proteins are targeted for 
degradation via the ER associated degradation (ERAD) system. Proteins targeted for 
degradation in the ER are specifically polyubiquitinated and transferred to the proteasome 
complex for degradation and recycling of the aminoacidic subunits. There are evidences 
that pendrin-GFP co-localizes with ubiquitin in the cell, suggesting therefore a role of 
polyubiquitination in pendrin degradation [126]. Furthermore, Lee et al. demonstrated the 
role of a specific ER-resident E3 ubiquitine ligase, namely Rma1, in the degradation of 
pendrin, both wild type and mutated. In the same article it was also shown the possibility to 
favor the glycosylation and subsequent trafficking of the protein to the plasma membrane 
by facilitating its maturation and folding. It is therefore feasible to hypothesize that also 
those pendrin variants investigated in the present study, displaying a folding defect, are 
targeted by polyubiquitination and delivered to the proteasome for degradation.  
 
In order to support this hypothesis, the protein abundance of the different pendrin 
variants was investigated and quantified both by fluorescent imaging of the fusion protein 
pendrin-EYFP and western blotting of the untagged protein. The results of quantification 
experiments show significant differences in the level of expression of the different pendrin 
variants, correlating quite well with the observed subcellular localization. Mutants that 
showed and impairment in trafficking and where retained in the ER (T193I, L445W) also 
showed the lower expression levels both in the imaging (Figure 14-16) and in western blot 
experiments (Figure 18-20). On the other hand, mutant variants showing a more efficient 
trafficking to the plasma membrane (P142L, C282Y) showed a level of expression 
significantly higher with respect to the most severely impaired mutants (T193I and 
L445W), even though reduced if compared to the wild type. 
 
The imaging quantification experiments have been performed both on total (Figure 
13-14) and plasma membrane (Figure 15-16) pendrin. As observed in the subcellular 
localization experiments, the mutant Q413R shows an unexpected behavior, displaying 
levels of expression comparable to the two loss of function mutants, T193I and L445W, 
while retaining significant function. Such result is anyway consistent with the co-
localization data, where the same mutant was shown being mostly retained in the ER. 
It is therefore to be concluded that pendrin mutants with a reduction or loss of 
function invariably show expression levels reduced with respect to the wild type, with the 
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most severe reduction in expression correlating with a retention in the ER. The expression 
levels of the fully functional variant R776C, as expected, were not reduced with respect to 
the wild type. 
 
These results were confirmed by the western blot experiments on total cellular 
extract and extracts of the total membranes fractions (Figure 19-20). Again, the 
functionally impaired mutants showed a very low level of expression. The pendrin variant 
P142L instead, showed an expression level significantly higher with respect to the most 
severely impaired mutants (T193I and L445W). In the western blots on total proteins 
(Figure 17-18), an anomalous phenomenon could be observed: the mutant P142L showed 
a level of expression comparable to the wild type or even higher in some individual 
experiments. Such unexpected result may be due to the accumulation of this particular 
mutant in form of inclusion bodies in the cytosol, circumventing degradation by the 
proteasome complex. Accordingly, this phenomenon is no more visible in the total 
membranes blots, where the expression level of P142L is significantly lower with respect 
to the wild type. Another anomaly of the western blot experiments is the total absence of 
signal in correspondence of the polymorphism R776C. This particular variants did not 
show any difference with respect to the wild type, neither in the functional tests, nor in the 
co-localization and imaging quantification experiments. An absence of signal is therefore 
only to be explained by an impaired antibody recognition due to the disruption of the 
epitope. The aminoacidic substitution R776C actually lies within the epitope recognized by 
the anti-pendrin antibody used in these experiments. 
 
It is important to underline that the western blot experiments where performed on 
cells overexpressing the untagged form of the protein, whereas imaging experiments 
where performed on fusion proteins. The correlation of the results from the two methods 
reinforce not only the particular piece of data, but also the validity of the two 
complementary experimental approaches. Specifically, the presence of the relatively bulky 
EYFP protein fused to the C-terminus does not seem to affect pendrin trafficking. 
Therefore we can conclude that the use of fusion proteins constitutes a valid approach for 
determining the subcellular localization of wild type pendrin and its variants. 
 
In Table 8, a summary of the functional and molecular characterization performed 
on the selected allelic variants is reported in order to underline the correlation between 
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determined functional impairment and molecular defect observed by co-localization and 
expression levels analysis experiments. 
 
 
 
 
The evaluation of expression levels leads to the assumption that hypo-functional or 
non-functional pendrin forms are targeted to the protein degradation pathways. 
Identification of the specific molecular defect is a precious information for the development 
of a therapeutic approach aiming to a functional rescue of the mutant forms, either by 
facilitating their folding or potentiating their activity, possibly after inhibiting their 
degradation. 
 
The efficacy of such an approach on hypofunctional and non functional forms of 
pendrin was also investigated in the present study.  
Func%on' Localiza%on' Expression'levels'
P142L& reduced& Plasma&Membrane&
G149R& reduced& Plasma&Membrane/ER&
C282Y& reduced' Plasma&Membrane& &&&&&
T193I& lost& ER&
Q413R& reduced& ER&
L445W& lost& ER&
R776C& unaﬀected& Plasma&Membrane& &&&&&&&*&
Table 8: summary of the functional and molecular characterization of the analyzed pendrin 
variants. Expression levels reported here correspond to the results from imaging on plasma 
membrane pendrin and compare each pendrin variant to the wild type. Dashed arrows in the 
fourth column indicate a mildly reduced level of expression. Boldface arrows indicate a more 
severely reduced level of expression. Double boldface arrows indicate an even more severely 
reduced level of expression. The dash indicates no difference in the expression level. One Way 
ANOVA with Bonferroni’s post-test. (*) not possible to confirm the result by western blotting. 
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Cells overexpressing wild type or mutated pendrin were treated with a potent 
proteasome inhibitor (MG132) in order to reduce the proteasomal degradation and its 
effect on transport activity and protein expression was analyzed. Pendrin expression levels 
upon treatment with MG132 or its vehicle were evaluated by fluorescence imaging of 
pendrin-EYFP. The analysis showed a dramatic increase in total pendrin expression 
(except for C282Y, Figure 22), with a massive accumulation of all pendrin variants in the 
ER, including the wild type and the polymorphism R776C. A similar effect was seen at the 
level of the plasma membrane (Figure 23), whereas in this latter case, the wild type and 
the polymorphism R776C were not affected. A general increase in the expression levels 
upon treatment with the proteasome inhibitor MG132 is confirming once more the 
hypothesis that pendrin mutants, as the wild type, undergo degradation via the ubiquitin 
proteasome pathway.  
 
The functional tests performed on cells treated with the same proteasome inhibitor 
further confirmed the efficacy of the treatment (Figure 21). A significant increase in 
transport function upon treatment with MG132 was observed for 4 mutants (P142L, T193I, 
Q413R, L445W) out of 8 pendrin variants analyzed (including the wild type). These 4 are 
the mutants with the most severely impaired transport function. In particular, one of the 
mutants (Q413R) shows and increase in transport activity of about one third following 
treatment with MG132 with respect to the vehicle. Interestingly, this is the same mutant 
showing an almost complete exclusion from the PM but retaining a significant transport 
activity, as mentioned earlier. This result reinforces once more the hypothesis that this 
particular mutation may on one side interfere with the correct maturation of the protein but 
on the other side confer an intrinsic activity advantage to the transporter.  
 
These results are highly promising for a possible development of the rescuing 
approach, showing that inhibition of proteasomal degradation does not only lead to a 
general increase in protein abundance, but, more importantly, that such a treatment leads 
to a protein increase at the level of PM and is also effective on restoring, at least partially, 
the function of the transporter.  
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5.2 Functional screening of pendrin ligands 
 
 
As mentioned in the introduction, pendrin overexpression and/or hyperactivity is 
linked to pathological states such as asthma, COPD and hypertension [12, 29, 90]. The 
transporter constitutes therefore a novel target for possible therapeutical approaches in 
such pathologies. So far, no specific and potent pendrin inhibitor could be identified, not 
even from the screening of large compounds libraries [34]. In the present study we tested 
41 compounds on pendrin chloride/iodide exchange activity in order to identify potential 
inhibitors/modulators of the transporter. The compounds included in the screening were 
selected among (i) known inhibitors of chloride channels and transporters and inhibitors of 
DRA, (ii) diuretics and antihypertensive agents and (iii) small compounds predicted by the 
bioinformatics approach called meta-analysis. The eventual identification of active 
compounds within these 3 groups was then exploited for a second phase selection by 
means of a similarity search based on the so-called SHED profiling of small compounds. 
The screening was performed by means of the fluorometric method developed by 
Dossena et al. in 2006 [69] and adapted for a semi-high-throughput approach as 
described in the methods. 
 
The results of the functional screening performed on potential pendrin ligands are 
summarized in Table 6. From the presented outcome, a peculiar pharmacological profile of 
pendrin can be identified, as discussed in the following.  
 
The first observation is that, surprisingly, the well known anion exchanger inhibitor 
DIDS was unable to affect pendrin iodide transport activity at the concentration of 100 µM 
(Figure 25), confirming the results obtained by Dossena et al. in 2006 with a different 
technique (radiolabelled chloride uptake) [97]. In a study from 1999, Scott et al. [99] did 
show an inhibitory effect of 1 mM DIDS on pendrin expressed in Xenopus oocytes and 
Soleimani et al. in 2001 showed a similar effect of 0.5 mM DIDS on pendrin transfected 
HEK 293 cells. Their findings are clearly in contrast with the result shown in the present 
study, where no inhibitory effect could be measured in HEK 293 Phoenix cells upon 
treatment with the same substance. Though, the contrasting results may be due to the 
different experimental set up and cellular system used for the evaluation of pendrin 
activity, but it is also to be underlined that the concentration used in the experiments of 
Scott et al. was 10 fold higher and in Soleimani et al. 5 fold higher than the concentration 
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used in the present study. In the same study, Scott et al. also showed an inhibitory effect 
of the diuretics probenecid and furosemide (1 mM), whereas in the present study we could 
not replicate the same results (Figure 31 and 35). Again, such difference may be due to 
the different experimental set ups and concentration tested. Another noteworthy result has 
been observed upon treatment with 100 µM NPPB. NPPB is a known inhibitor of chloride 
channels but it is not expected to inhibit anion exchangers [127]. We could show that 
treatment of pendrin transfected cells with NPPB was effective in reducing iodide influx 
with respect to vehicle treated cells (Figure 24), confirming the results shown by Dossena 
et al. in 2006 with a different technique [97]. In the same study, Dossena et al. could show 
the inhibitory effect of the DRA inhibitor niflumic acid.  
 
Niflumic acid is known to exert its anti-inflammatory action via cyclooxygenase 
inhibition [128], but it is also involved in the modulation of chloride channels, such as CLC-
Ka and ClC-Kb [129]. DRA, also known as SLC26A3, is the closest analogue of pendrin, 
the two proteins showing 44% of identity and a 60% of similarity. A few inhibitors of DRA 
have been assessed so far, none of them anyway specific, but they may represent a 
useful source of potential pendrin ligands. In the present study we tested known inhibitors 
of DRA, namely the anti-inflammatory drug niflumic acid, the anti-rheumatic drug tenidap 
and the anti-diabetic drug glibenclamide. The latter failed in reducing pendrin iodide 
transport activity at a concentration of 100 µM (Figure 30), but treatment with niflumic acid 
at the same concentration was successful in reducing iodide influx in pendrin transfected 
cells (Figure 28). As mentioned earlier, these data confirm the results previously obtained 
with a different technique [97], thus proving once more the validity of the fast-fluorometric 
method [69] exploited in the present study. Nilfumic acid was also the only compound 
showing an inhibitory effect on pendrin identified in a screening of a 5,000 compounds 
library by Pedemonte et al. in 2007 [34]. In some cases, a reduction of EYFP fluorescence 
following exposure to niflumic acid, independent from the iodide influx and possibly due to 
an intracellular acidification [130], has been observed. An excessive reduction in EYFP 
fluorescence may impair an exact evaluation of the effect of the drug itself on the iodide 
influx. 
 
The most interesting and original result from the present study has been obtained 
upon treatment with the third DRA inhibitor mentioned earlier, tenidap [106]. Tenidap is an 
anti-rheumatic, anti-inflammatory drug effective against rheumatic arthritis [131]. Its action 
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is related to cyclooxygenases 1 and 2 and lipooygenase 5 inhibition, but it is known to 
modulate also a number of membrane transporters and channels including the rat kidney 
Na+/HCO3- cotransporter (rkNBC) [132] and the inwardly rectifying K+ channel Kir2.3 [133]. 
Treatment of pendrin transfected cells with 100 µM tenidap showed a very strong (85%) 
inhibitory effect on iodide transport activity in comparison to cells treated with the vehicle, 
which represents the most potent inhibitory effect on pendrin activity observed so far 
(Figure 29). This work provides therefore the first evidence of a strong inhibitory effect of 
tenidap on pendrin iodide transport activity. Even if tenidap cannot be considered a 
specific pendrin inhibitor, the finding still constitutes a precious source of information for 
further prediction of putative pendrin ligands. 
 
The identification of the abovementioned active compounds has been exploited as 
a starting point for further refinement of the list of screening targets. Such refinement was 
achieved by aligning the molecule of interest against a small compounds database 
(www.drugbank.ca), by means of the so-called SHED profile of the molecules. A similarity 
analysis has been therefore performed using both tenidap and niflumic acid as templates. 
Both alignments delivered a new list of compounds with a high SHED profile similarity 
score with the respective templates of origin. Despite the great variety of chemical and 
pharmacological classes of the predicted compounds, according to the similarity of their 
SHED profiles, they are expected to have a similar pharmacological profile and therefore 
show a similar effect on pendrin. A number of compounds have been identified this way as 
potential pendrin ligands to be functionally screened. The results of this second phase of 
the screening are reported in Table 6, section 4b.  
 
Two of the compounds resulting from the SHED alignment of tenidap and niflumic 
acid actually showed an effect on iodide influx in pendrin transfected cells during the 
functional tests.  
 
N-(2-chlorophenyl)-2-(2,4-dibromophenoxy)acetamide, derived from the SHED 
alignment of tenidap, showed a 14% pendrin activity inhibition with respect to the vehicle 
(Figure 44). At the same time though, an alteration of fluorescence decrease in control 
(not expressing pendrin) cells was measured upon treatment with the same compound 
with respect to the vehicle treated cells. An effect on control cells would hint to a 
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disturbance of endogenous transports interfering therefore with an exact evaluation of the 
effect on pendrin.  
 
The second active compound emerged from the SHED alignment of niflumic acid, 
and it is the non-steroidal anti-inflammatory drug flufenamic acid. Treatment of pendrin 
transfected cells with flufenamic acid resulted in a 15% pendrin activity inhibition with 
respect to vehicle treated cells (Figure 55). As observed upon treatment with niflumic acid 
though, a reduction of EYFP fluorescence following exposure to flufenamic acid, 
independent from the iodide influx, has been observed, possibly due to intracellular 
acidification [130]. As it is the case of niflumic acid therefore, a reduction in EYFP 
fluorescence may impair an exact evaluation of the effect of the drug itself on the iodide 
influx. 
 
Despite the unspecificity of the active compounds resulting from the screening, their 
identification is again a precious source of information for further refinement of the search 
for more specific and potent pendrin ligands. From the analysis of the identified 
compounds it is possible to isolate molecular or chemical features that may be important 
for the affinity with the target protein. This peculiar feature can in turn drive the further 
research of active compounds. In the present study we confirmed the alignment of small 
compounds according to the SHED profiling as a successful bioinformatics approach for 
identifying potential ligands of a protein of interest.   
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6. Conclusions 
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Functional and molecular characterization and rescue of pendrin 
variants 
 
In this study we performed the functional characterization of 7 uncharacterized 
pendrin variants identified in the genetic screening of a cohort of 58 deaf patients with or 
without EVA, performed at the Hospital of Campinas, Sao Paolo, Brazil. Based on the 
results of the functional test, 4 pendrin variants (P142L, G149R, C282Y and Q413R) were 
classified as mutations with reduction of function, 2 (T193I and L445W) as mutations with 
complete loss of function and one (R776C) as a benign polymorphism. These results 
contributed to define the genetic diagnosis of deafness for 4 patients out of 14 presenting 
pendrin mutations. For 3 of these patients deafness was assessed as linked to pendrin 
dysfunction, while for one patient we were able to exclude pendrin as the genetic cause of 
deafness. Including our findings, the genetic diagnosis was conclusive for 6 patients, while 
for 8 individuals, bearing monoallelic pendrin mutations, further investigations are needed, 
as it is possible that other genetic or environmental factors are determining the phenotype. 
Further investigation must include the sequencing and characterization of pendrin 
promoter and 3’ untranslated region, which may play a role in regulating the expression of 
the transporter.  
 
For what concerns the subcellular localization of the analyzed pendrin variants, we 
could identify forms ranging from a complete retention in the ER (T193I, Q413R and 
L445W), to a mixed behavior (G149R) or trafficking to the plasma membrane 
undistinguishable from the wild type (P142L, C282Y, R776C). The localization of the 
different forms correlates well with the respective functional impairment, with the loss of 
function mutants being retained in the ER (T193I, L445W) and the variants with residual or 
unaffected function being localized to the PM (P142L, G149R, C282Y, R776C). The only 
exception is the mutant Q413R, showing a near to complete retention in the ER but also a 
residual transport activity, for which an intrinsic gain of function could be hypothesized. 
 
Expression levels of the different pendrin variants, analyzed both via imaging and 
western blot, are reduced for all functionally impaired variants. The lower expression levels 
were observed for those mutants retained in the ER, while for variants capable of reaching 
the PM the reduction of expression levels was milder. The picture obtained in this study 
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confirms that functionally impaired pendrin forms are largely, but not exclusively, retained 
in the ER and degraded, possibly via ER associated degradation (ERAD).  
 
The definition of the specific molecular defect allows for the investigation of a 
possible rescuing approach. In this sense we could show that by inhibiting the 
proteasomal degradation it was possible not only to increase the global expression levels 
of the mutants, but also their expression at the PM. Importantly, also the transport activity 
was significantly recovered in 4 out of 6 characterized mutants, upon treatment with 
MG132. 
 
The evidence of a recovery of the transport activity of pendrin hypo-functional forms 
opens the way to a number of possible therapeutical approaches. It is therefore possible to 
hypothesize that a targeted approach aimed to the modulation of the degradation and/or 
folding assistance of defective pendrin forms may be the key for a future treatment of 
pendrin related deafness and Pendred syndrome. 
 
 
Ligands screening 
 
Screening of large compound libraries failed in delivering any specific ligand for 
pendrin. By means of a more targeted approach, we were able to identify a number of 
putative pendrin ligands to be confirmed by functional testing. The functional screening 
could be performed in a semi-high-throughput fashion thanks to the same fluorometric test 
used for the functional characterization of pendrin variants. 
 
The screening of the candidate ligands led to the confirmation of the effect of 
previously identified inhibitors (NPPB and niflumic acid, showing 32 and 28% inhibition, 
respectively), therefore reinforcing once more the validity of the technical approach. 
Furthermore, we were able to identify previously unknown pendrin modulators. In 
particular, the first of the newly identified pendrin inhibitors was the anti-inflammatory drug 
tenidap. Short term treatment with 100 µM tenidap showed a strong inhibition (85%) of the 
iodide influx in pendrin transfected cells with respect to the vehicle treated cells. Even if 
this particular compound cannot be regarded to as specific for pendrin inhibition, its 
structure is a precious piece of information for further refinement of the ligand search. 
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From the active compounds identified (niflumic acid and tenidap), structure 
alignments according to the SHED profile principle have been performed, in order to 
identify further candidate compounds to be screened. N-(2-chlorophenyl)-2-(2,4-
dibromophenoxy)acetamide, predicted by tenidap alignment, did show a slight (14% 
inhibition) effect on iodide influx in pendrin transfected cells. A further active compound 
identified, flufenamic acid, was predicted by the SHED alignment of niflumic acid, and did 
show a 15% inhibition of pendrin-dependent iodide transport.  
 
To conclude, we were able to identify active compounds capable of inhibiting 
pendrin transport activity and exploit this information to further refine the selection of 
putative ligands by means of the bioinformatic approach defined as SHED alignment. The 
identification of pendrin inhibitors may represent an important step in the treatment of 
pathological conditions associated to an increased pendrin function or expression, such as 
bronchial asthma, COPD and hypertension.  
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